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Abstract 
Microbial molecules have evolved to promote transient and/or permanent 
associations with mammals. Although numerous examples of secretion systems 
employed by pathogens during infection have been described, mechanisms by which 
commensal bacteria export molecules during symbiosis remain unknown. The human gut 
mutualist Bacteroides fragilis produces a capsular polysaccharide (PSA) that directs host 
immune development. We reveal herein that outer membrane vesicles (OMVs) deliver 
PSA to dendritic cells (DCs), promoting development of regulatory T cells and inducing 
anti-inflammatory cytokines during in vivo protection of intestinal disease. OMV 
mediated regulatory responses required the Growth Arrest and DNA-Damage-Inducible 
protein (Gadd45α) in DCs. DCs treated with OMVs containing PSA protect mice from 
experimental colitis, whereas Gadd45α-/- DCs are unable to support T cell regulatory 
response and are defective in suppressing proinflammatory cytokine production and host 
pathology. Our findings demonstrate DC-induced protection from disease via interaction 
with a beneficial microbial molecule delivered by OMVs, uncovering a novel paradigm 
for interkingdom communication between the microbiota and mammals.  
In another effort to test the immunomodulatory activity of PSA outside of the gut, 
we found systemic treatment with PSA protects animals from experimental sepsis, a 
model for systemic inflammatory disease. More interestingly, this protection is mediated 
by B cells but not T cells because Rag-/- mice reconstituted with B cells gained the 
protection by PSA while those reconstituted with T cells were not protected. We further 
showed that a subset of B cells, marginal B cells, which are known to produce natural 
antibodies against bacterial antigens, were sufficient in mediating this protection. 
vii 
Preliminary data also suggested that secretion of IgM and/ or expression of type II 
Interleukin 1 receptor (IL-1R2) from marginal zone B cells might be critical for the 
suppression of the excessive inflammation during disease.  This study will help to 
uncover the systemic effect of PSA, a microbial molecule from a gut commensal, and its 
potential as a novel therapy for human sepsis.
viii 
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1.1 Host-Microbial Homeostasis: Active Immunomodulation 
by Gut Microbiota 
Immediately after birth, all mammals are initiated into a life-long colonization of 
foreign microorganisms on almost all environmentally exposed surfaces including skin, 
mouth, gut and vagina (Dethlefsen et al., 2007). Among these areas, the gastrointestinal 
tract is the primary site of host-bacterial interactions. It is evident that maintenance of the 
association between the gut microbiota and host tissue is established via constant and 
complex crosstalk between the commensal bacteria, the gut epithelium and the intestinal 
immune cells.?
The gut-associated immune system has evolved to tolerate the commensals 
through various mechanisms, including the secretion of a thick mucus layer by goblet 
cells in the intestine (Deplancke and Gaskins, 2001), the production of antimicrobial 
peptides by Paneth cells and the production of IgA by B cells (Macpherson et al., 2000; 
Macpherson et al., 2001a; Macpherson et al., 2001b; Macpherson and Uhr, 2004). Such 
mechanisms restrict the microbiota from directly contacting host tissues and prevent the 
penetration of commensals across the epithelial barrier.  
Nevertheless, the constant interaction between the commensals and the epithelium 
is inevitable because stable colonization of the microbiota requires close contact of 
bacteria with mucosal surfaces. Pattern Recognition Receptors (PRRs), such as Toll-like 
Receptors (TLRs) and Nucleotide-binding, oligomerization domain (NOD)-like receptors 
(NLRs), are expressed on intestinal epithelial cells to specifically monitor the microbial 
components in the intestinal lumen.  These receptors can trigger downstream immune 
responses once bound with Microbes Associated Molecular Patterns (MAMPs) in the 
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lumen, which may lead to host inflammation and elimination of gut microbes. Therefore, 
stable colonization of gut commensals requires regulatory mechanisms to dampen the 
constant inflammatory responses that the microbiota may induce in healthy hosts. Indeed, 
such mechanisms are being extensively studied and are shown to vary among bacterial 
species. For example, some commensals have evolved to have surface molecules that are 
less immunogenic, which protect them from being recognized as foreign antigens by the 
host immune system. Moreover, since germ-free mice do not have a fully functional 
immune system (Round and Mazmanian, 2009a; Smith et al., 2007), it was strongly 
implicated that the gut commensals may actively shape the innate and/ or adaptive 
immune responses and promote the health of the host.  
1.1.1 Downregulation of Innate Immunity by Commensal Bacteria 
 PRRs, such as TLRs, play essential roles in innate immunity in response to 
microbial ligands. They are cell surface or intracellular molecules that recognize 
microbe-specific molecules and trigger intracellular signaling cascades, which may lead 
to the activation of several transcription factors (e.g., NF-κB, AP-1, IRF-3, -7). These 
transcription factors can drive the transcription of genes involved in proinflammatory 
responses and hence induce inflammation (Takeda and Akira, 2005). 
Recently, several studies have demonstrated that commensal organisms may 
target and inhibit NF-κB activation to suppress inflammation. By analyzing the 
composition of the intestinal microbiota of Crohn’s disease patients, Sokol et al. 
identified Faecalibacterium prausnitzii, which is greatly reduced in Crohn’s disease 
patients, as an anti-inflammatory commensal bacterium in the gut. They showed that the 
supernatant of F. prausnitzii inhibited NF-κB activation in a human intestinal epithelial 
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cell line and suppressed proinflammatory cytokine production both in vitro and in a 
mouse model of colitis (Sokol et al., 2008). However, the underlying molecular 
mechanism remains unknown.?
 The activation of NF-κB is regulated by its inhibitor, IκB. Phosphorylation, 
ubiquitination, and degradation of IκB allow NF-κB to translocate into the nucleus, bind 
to specific DNA motifs, and induce transcription of target genes (Karin and Ben-Neriah, 
2000). An in vitro study by Neish et al. showed nonpathogenic Salmonella typhimurium 
could inhibit IκBα degradation and in turn prevent NF-κB from entering the nucleus in 
human epithelial cells so as to reduce NF-κB-mediated proinflammatory response (Neish 
et al., 2000). Furthermore, a prevalent commensal bacterium of the human intestinal 
microbiota, Bacteroides thetaiotaomicron, was shown to attenuate proinflammatory 
cytokine production from epithelial cells in vitro and prevent pathology in epithelial 
tissues in vivo. The anti-inflammatory activity of B. thetaiotaomicron is achieved by 
facilitating the nuclear export of NF-κB subunit RelA in a PPARγ-dependent manner, 
which largely decreases the transcription of NF-κB-mediated proinflammatory genes 
(Kelly et al., 2004). ?
Although TLR/NOD signaling typically results in proinflammatory responses 
toward microbes, there are studies suggesting that they might also play important roles in 
sensing molecules derived from commensals and eliciting responses counteracting the 
inflammation. For example, Lai et al. found that after skin injury, Staphylococcus 
epidermidis, a member of the skin microbiota, could suppress the release of 
proinflammatory cytokines in keratinocytes and inhibit tissue inflammation in vivo. LTA 
derived from Staphylococcus epidermidis, which is responsible for the anit-inflammatory 
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effect, was found to signal through TLR2 to induce the expression of TRAF1, a negative 
regulator of TLR3-mediated NF-κB activation in keratinocytes (Lai et al., 2009). 
However, this and other studies have also shown that LTA can induce proinflammatory 
responses in other cell types, such as macrophages, monocytes (Timmerman et al., 1993), 
and mast cells (Yoshioka et al., 2007). This brings up the question as to how TLRs 
differentiate signals from commensals and pathogens and initiate signaling cascades with 
seemingly opposite consequences. One explanation proposed by Lai et al. was that TLRs 
might function differently depending on their proximity to microbes. Therefore, since 
keratinocytes are constantly exposed to the skin microbiota and have a greater chance of 
interacting with commensal-derived molecules, their TLRs may act as anti-inflammatory 
mediators. 
In addition to directly targeting TLR-mediated signaling to suppress inflammation 
in cells that are in close contact with the microbiota, commensals have also evolved ways 
to modulate innate immune responses of other cell types, such as neutrophils.  Maslowski 
et al. found that short chain fatty acids (SCFAs) produced during fermentation of dietary 
fiber by intestinal commensals, could interact with G-protein-coupled receptor 43 
(GPR43) expressing neutrophils to attenuate inflammation during experimental colitis, 
arthritis, and asthma (Maslowski et al., 2009). This is an interesting finding because it 
connects the diet with the composition of the microbiota and the host immune response. 
In addition, it may also explain the difference among individuals in their susceptibility to 
human inflammatory or autoimmune diseases in different geographical regions. 
Taken together, the innate immune system of the host, while serving as the early 
defense mechanism against pathogenic agents, also provides a platform for commensal 
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organisms to exert their influence on during the establishment of stable colonization, 
therefore promoting host–microbial homeostasis. 
1.1.2 Induction of T cell-dependent Regulatory Responses by Commensal 
Bacteria 
Beside their effects on innate immune responses, commensals also play a role in 
shaping the adaptive immune responses to achieve host–microbial homeostasis. 
Regulatory T cells (Tregs) are a major cell population involved in adaptive 
regulation of inflammatory responses. Tregs are marked by the expression of a master 
transcription factor, Foxp3 (Fontenot et al., 2005). Once differentiated and activated, 
Tregs downregulate inflammatory responses by secreting anti-inflammatory cytokines 
(e.g. IL-10), suppressing effector T cell responses, and inhibiting the activation of 
dendritic cells or macrophages (Vignali et al., 2008). Recently, several studies have 
demonstrated that some commensal bacteria or molecules derived from them may induce 
Treg differentiation and/ or release of anti-inflammatory cytokines. For example, 
O’Mahony et al. showed that mice fed with Bifidobacterium infantis were protected from 
pathogenic Salmonella typhimurium-stimulated-inflammation by the induction of a Treg 
population. Normally the inflammation induced by pathogenic bacteria could be 
excessive and result in tissue damage if host immune system fail to control it. 
Mechanistically, adoptive transfer of Tregs induced by B. infantis greatly suppressed NF-
κB activation in vivo and depletion of these Tregs abolished this suppression, suggesting 
that these Tregs are both required and sufficient for the anti-inflammatory activity of B. 
infantis (O'Mahony et al., 2008). Similarly, an in vitro study showed that B. infantis 
inhibited the production of proinflammatory cytokine IL-17 and induced the release of 
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anti-inflammatory cytokine IL-10 in cultured murine splenocytes stimulated by TGF-β 
and IL-6 (Tanabe et al., 2008). Interestingly, a pathobiont Helicobacter hepaticus, can 
also induce a Treg population and adoptive transfer of these Tregs into 
immunocompromised hosts prevented colitis triggered by H. hepaticus infection in an IL-
10-dependent manner (Kullberg, 2002). In addition, new evidence has further suggested 
that Tregs may also help to promote IgA production from B cells in order to maintain 
host-microbial homeostasis (Cong et al., 2009).  
In our lab, an in vivo study revealed that polysaccharide A, a surface molecule of 
a prominent commensal bacterium of the human gut, Bacteroides fragilis, could protect 
animals from experimental colitis induced by either CD4+ CD45Rbhigh T cell transfer or 
trinitrobenzene sulfonic acid (TNBS). And such protection was mediated by the induction 
of IL-10 producing CD4+ T cells (Mazmanian et al., 2008a). How that 
immunomodulatory molecule, PSA, is delivered from the bacterium to the immune cells 
is part of this thesis.  
The maturation and activation of DCs direct T cell differentiation into various 
lineages. Several studies have investigated the influence of commensal organisms on DC 
functioning.  Christensen et al. showed that various Lactobacillus strains differentially 
modulated DC maturation and cytokine production. L. reuteri DSM12246 was 
incompetent in eliciting proinflammatory cytokines, such as IL-12, IL-6, and TNFα, from 
DCs. But it could induce anti-inflammatory cytokine IL-10 production and suppress those 
proinflammatory cytokines triggered by L. casei CHCC3139 (Christensen et al., 2002). 
Such observations indicate that regulation between closely related commensal organisms 
might be a mechanism to limit inflammation toward beneficial bacteria and maintain 
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homeostasis. Likewise, Baba et al. tested the effect of eight different commensal bacteria 
on the maturation of DCs. Although different species induced distinct cytokine profiles in 
DCs, most of them directed DCs to promote suppressive CD4+ T cell differentiation in 
vitro (Baba et al., 2008). But the cellular mechanisms underlying these observations 
remain unknown. Taken together, these studies suggest that DCs may be an important 
mediator for Treg induction during the interaction between commensals and host 
adaptive immune system.?
One remaining question is whether the induction of Tregs by commensal bacteria 
can render the host immunocompromised. If not, how is the immunosuppressive activity 
of the commensal-induced Tregs regulated? One intriguing hypothesis is that commensal 
bacteria induce antigen-specific Tregs so that Tregs induced by one bacterial species only 
suppresses the inflammatory response toward this particular baterium. This hypothesis 
offers a new angle to examine the influence of the microbiota on host adaptive immune 
system. However, it is still unclear whether the Treg response exhibits antigen specificity, 
and if so, what the underlying mechanism is. 
Commensal organisms actively interact with both the innate and the adaptive 
immune systems to achieve their long-term colonization within the host. Investigations of 
how commensal organisms and their hosts communicate will continue to enhance our 
understanding of how the host-microbial homeostasis is achieved. In addition, a better 
understanding of the underlying molecular mechanisms may greatly advance the 
development of new therapies for inflammatory or autoimmune diseases.
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1.2 Host-Microbial Communication: Outer Membrane 
Vesicles (OMVs) 
Microbes have evolved complex adaptations to inhabit and replicate in numerous 
ecological niches on Earth. Animals are no exception, and provide an ideal environment 
for both transient and permanent microbial colonization. Many pathogens cause acute 
infections as a means to propagate and disseminate, and accordingly have developed 
myriad mechanisms to avoid, subvert and/or prevent host immune responses (Merrell and 
Falkow, 2004). Conversely to pathogens, symbiotic bacteria have taken a different 
evolutionary route to promote bacterial replication. The gastrointestinal tract of mammals 
is colonized for life with a diverse commensal microbiota that provides essential benefits 
to the host such as nutrient and caloric extraction from food, development of the immune 
system and protection from immunologic and metabolic diseases (Dethlefsen et al., 2007; 
Flint, 2004; Round and Mazmanian, 2009b). Therefore unlike most pathogens that 
acutely infect animals for days or weeks, symbiotic bacteria have evolved to improve 
host health, providing themselves a protected niche where they flourish for decades. The 
dichotomy between beneficial and harmful microbes is illustrated by studies showing that 
gut colonization by the microbiota inhibits infection by enteric pathogens (Reid and 
Bruce, 2006; Servin, 2004; Tilman, 2004). 
How do bacteria establish molecular communication with their hosts to promote 
microbial replication? In addition to the export of single proteins (such as toxins) by the 
general secretion pathway, gram-negative bacteria have evolved intricate mechanisms 
that can deliver a concert of microbial molecules to the host. Well-studied examples 
include type III secretion systems (T3SS), T4SS and T6SS, which assemble 
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macromolecular surface appendages that translocate bacterial effectors following direct 
contact with host cells (Galan, 2009). In addition, the cell membrane of most gram-
negative bacteria and some gram-positive bacteria have the dynamic feature of releasing 
outer membrane vesicles (OMVs) (Lee et al., 2009). OMVs were first described in the 
1970s in Escherichia coli (Hoekstra et al., 1976) and later were found in both pathogenic 
and nonpathogenic bacterial species (Beveridge, 1999), such as Pseudomonas aeruginosa 
(Kadurugamuwa and Beveridge, 1995) and Helicobacter pylori (Fiocca et al., 1999).  
During the past four decades, more and more studies on OMVs revealed their role 
in mediating bacterial-bacterial communication and more significantly, in delivering 
virulence factors to host cells during infections (Kuehn and Kesty, 2005). For example, 
heat-labile enterotoxin (LT), which disrupts electrolyte balance in the gut endothelium, is 
found to be associated with and even enriched in enterotoxigenic E. coli (ETEC) OMVs 
(Horstman and Kuehn, 2000). However, there are no reports so far showing whether or 
how bacterial OMVs could mediate beneficial effects during microbial-host interactions. 
Notably, a fundamental difference between surface secretion systems and OMVs is the 
distance that microbial molecules can travel. As commensal bacteria generally do not 
make intimate contact with host cells, OMVs appear to provide a suitable mechanism for 
members of the microbiota to deliver molecules to distant targets in the host.
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1.3 Microbiota and Diseases: Inflammatory Bowel 
Diseases (IBDs) and Sepsis 
1.3.1 Inflammatory Bowel Diseases (IBDs) 
IBDs are chronic and relapsing inflammatory conditions of the gastrointestinal 
tract. The major types of IBDs are Crohn’s disease and ulcerative colitis. Crohn’s disease 
could affect any part of the digestive system while ulcerative colitis is usually restricted 
to colon. Clinical symptoms of both diseases are similar, including abdominal pain, 
diarrhea, weight loss and so on. Current treatments of IBDs focus on reducing the 
uncontrolled inflammatory responses (e.g. TNF inhibitors) or suppressing the immune 
responses in general (e.g. steroids).  
Clinical studies of human IBD patients as well as studies using animal models of 
IBDs have revealed that the pathogenesis of the disease is driven by multiple factors, 
including host genetic background and various environmental triggers, especially the 
intestinal microbiota (Packey and Sartor, 2008). 
Family and twin studies showed that offspring of two IBD parents has more than 
30% risk of developing disease and monozygotic twins exhibited concordance rate of 
20% to 50%. These observations strongly suggested that host genetics significantly 
contributes to disease susceptibility (Halme et al., 2006). Indeed, genetic studies, 
especially genome wide association studies, have identified several genes that are closely 
linked to IBD susceptibility in human (Van Limbergen et al., 2009). For instance, Nod2 
was the first gene found to be associated with IBD and therefore also named IBD1 
(Hampe et al., 2007; Hugot et al., 2001; Ogura et al., 2001). Nod2 is an intracellular PRR 
for recognizing muramyl dipeptide (MDP), the minimal motif of bacterial peptidoglycan. 
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Mutations that disrupt the function of Nod2 impair the detection of bacteria by host cells, 
and have been implicated in the pathogenesis of IBD (Kufer et al., 2006). Many other 
PRRs, such as TLR1, TLR2, TLR4 and TLR6, were also found to be associated with the 
disease (Franchimont et al., 2004; Pierik et al., 2006; Rioux et al., 2007). These studies 
strongly implicated that some gut bacteria might be one of the causes of the disease. 
However, so far there is no clear evidence showing the involvement of a certain gut 
bacteria in the initiation of IBD (Macfarlane et al., 2009).  
Despite the potential link between the gut microbiota and the pathogenesis of 
IBD, antibiotic treatment has not been very successful in treating IBD. The failure of 
antibiotic treatment for IBD as well as the observation that the composition and diversity 
of the intestinal microbiota were stustaintially altered in IBD patients (Scanlan et al., 
2006) has led to a hypothesis that the imbalance of the normal microbiota, also known as 
dysbiosis, may also contribute to the disease (Krinos et al., 2001; Ley et al., 2007; 
Mazmanian et al., 2008b). Although it is still not clear that whether dysbiosis of the 
microbiota is a result of IBD or the cause of inflammation during disease, some 
commensals were found greatly reduced in human IBD patients, leading to a notion that 
gut commensals could also be protective rather than pathogenic in IBD. Recent studies 
demonstrated that some members of the normal microbiota, e.g. Bacteroides fragilis and 
Clostridium species, have the capacity to induce regulatory T cell response (Atarashi et 
al., 2011). Therefore the reduction of Firmicutes and Bacteroidetes in the microbiotas of 
IBD patients comparing to healthy individuals (Frank et al., 2007) supported the idea that 
IBD may result from the loss of one or more protective microbes in the microbiota. 
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1.3.2 Sepsis or Septic Shock 
When excessive inflammation occurs systemically and starts causing pathology in 
multiple organs, it is considered as sepsis or septic shock (Stearns-Kurosawa et al., 2010). 
Sepsis is the third-most common cause of death in the U.S. and kills more than 215,000 
people per year. According to a report published by the Centers for Disease Control and 
Prevention (CDC) in 2011, sepsis-related hospitalization has increased more than two 
times from 2000 to 2008 (621,000 to 1,141,000).  
When an infection occurs, the host mounts an appropriate inflammatory response 
to control the infection. The inflammation normally reduces once the source of infection 
is cleared. However, sepsis develops following an infection that is uncontainable and 
unclearable by the host. As a result, the uncontrolled inflammation causes endothelial 
damage or dysfunction, which could lead to multiple organ failure or even death. The 
mortality rate of sepsis ranges from 28% to 47% (Buras et al., 2005). Current treatments 
for sepsis include broad-spectrum antibiotics, anti-TNFα monoclonal antibody, etc., most 
of which are aimed to limit aberrant inflammation. However, none of them proved to be 
highly effective because of the heterogeneity of the causes or the stages of the disease in 
human patients.  
The development of sepsis can be divided into two stages. Right after infection, a 
rapid inflammatory response is crucial for bacterial clearance. Therefore, during the first 
stage, limiting inflammation does not help to control the disease. But once the infection is 
cleared, inflammation should be reduced to a minimum level in order to prevent tissue 
damage. So anti-inflammatory therapy could be useful at the second stage. In all, 
choosing appropriate treatments for patients at different stages of the disease is critical in 
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the current medical practice as well as in the research and development of new therapies. 
Although a lot of the sepsis cases are initiated by severe infections caused by 
pathogenic bacteria, translocation of microbiota from the gut into systemic circulation 
under some circumstances may also be an important factor of disease development 
(MacFie et al., 1999). Being one of the causes for sepsis, microbiota can also be 
protective against sepsis during surgeries.  It has been shown that peri-operative 
modulation of the gut microbiota may beneficially influence surgical outcome (Kinross et 
al., 2009). Therefore, investigating the protective influence of gut commensals or the 
molecules derived from them on sepsis would improve our understanding of microbiota’s 
role in the progression or the treatment of this systemic inflammatory disease. 
Animal models of septic shock are widely used in studying the development and 
treatment of human sepsis. Lipopolysaccharide (LPS)-induced endotoxic shock model is 
a relatively simple model (Wichterman et al., 1980). LPS is the major immunogenic 
component of the cell wall of gram-negative bacteria and it can trigger rapid pro-
inflammatory cytokine production, for example, IL-6 and TNF-α, of the host cells. When 
administered in high dose, it induces a hypodynamic cardiovascular state, which mimics 
clinical symptoms of human sepsis. However, this model has quite a few caveats. First of 
all, a single toxin (LPS) may not induce the same responses as bacterial pathogens do in 
human sepsis. Secondly, LPS induces an extremely rapid response while human sepsis is 
a prolonged process. Lastly, human is much more susceptible than mouse toward LPS-
induced endotoxic shock. Therefore, findings from this particular mouse model may not 
directly apply to human sepsis. Another experimental sepsis model is cecal ligation and 
puncture model (Rittirsch et al., 2009). Basically, a longitudinal incision is made in the 
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middle of the mouse abdomen. Then cecum is pulled out of the body cavity and its tip 
(1/2 to 2/3 of the entire length of the cecum) is ligated before one or two punctures are 
made by needles to allow cecal content that includes tons of bacteria to get into the body 
cavity to induce systemic infection. Different levels of the disease can be induced by 
varying the length of the ligated cecum, the size of the needle and the number of 
punctures. This is considered a better model than the LPS model because it mimics an 
infection caused by a group of naturally existing bacteria in the mouse.  
 
As discussed earlier, the gut microbiota has profound influences on host immune 
responses. Although the mechanism underlying the interaction between pathogenic 
bacteria and the host has been extensively studied, how commensals communicate their 
regulatory signals to the host, and how such interaction benefits the development of the 
host immune system are still largely unknown. Moreover, how this beneficial 
communication differs from that between pathogenic bacteria and the host also remains 
to be uncovered. Herein I used Bacteroides fragilis as a model commensal organism to 
address these questions. It has been shown that PSA, an immunomodulatory molecule of 
B. fragilis, contributes to the development of the host immune system and protects the 
host from experimental colitis. My research aimed to further understand the delivery 
mechanism of PSA to the host, and how this mechanism benefits the host.  
In Chapter 2, I describe my work that led to the discovery of outer membrane 
vesicles (OMVs), a single membrane bound structure present in most gram-negative 
bacteria and some gram-positive bacteria, as a possible mechanism for B. fraglilis to 
deliver PSA to the host and the anti-inflammtory responses induced by PSA-containing 
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OMVs. It was the first time that OMVs has been shown to mediate beneficial effect 
between microbes and the host. 
In Chapter 3, I present that, by whole genome microarray analysis on DCs that 
were treated with PSA-containing OMV, I identified Growth Arrest and DNA Damage 
Protein (Gadd45α) as a key component in DCs that mediates the immunomodulatory 
activity of PSA. This was the first intracellular signaling molecule that was found to be 
required for PSA’s activity. And this study will help us unravel the entire signaling 
pathway that PSA triggers in the host. 
Taken together, Chapters 2 and 3 uncover a novel communication paradigm 
between commensal bacteria and the host, and shed the first light on the molecular 
mechanism that underlies such beneficial communication. 
In Chapter 4, I show the work from Dr. June Round and myself, investigating the 
systemic effect of PSA in two murine models of sepsis. We show that systemic treatment 
with PSA protects animals from experimental sepsis via Marginal Zone (MZ) B cells. 
The fact that the protective activity of PSA during experimental colitis (local) and 
experimental sepsis (systemic) is mediated by T cells and B cells, respectively, 
suggesting that PSA from gut commensal B. fragilis, may have evolved to employ 
independent cellular and molecular pathways to influence the immune system of the host. 
Additionaly, this study has also provided supporting evidence that PSA, as a potent anti-
inflammatory microbial molecule, could be a potential therapy for human sepsis.?
Finally, Chapter 5 concludes with a discussion of the implication of my study 
(Chapters 2 and 3) and some potential directions for further studies (Chapter 4).?
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Chapter 2 
Outer Membrane Vesicles Deliver a Microbial 
Symbiosis Factor to Dendritic Cells and 
Protect Host against Intestinal Inflammation
18 
2.1 Summary 
Of the numerous microbial species that inhabit the gastrointestinal tract of 
mammals, Bacteroidetes are the most abundant gram-negative bacterial phylum (Ley et 
al., 2008). Bacteroides fragilis is a commensal that aids in host health by ameliorating 
inflammatory bowel disease (IBD) and multiple sclerosis (MS) in animal models 
((Mazmanian et al., 2008b; Ochoa-Reparaz et al., 2010a; Ochoa-Reparaz et al., 2010b). 
Polysaccharide A (PSA) is an immunomodulatory molecule produced by B. fragilis that 
is required and sufficient for treatment of experimental disease ((Mazmanian et al., 
2008b; Ochoa-Reparaz et al., 2010a). B. fragilis protects animals by inducing the 
development of interlekin-10 (IL-10)-producing CD4+Foxp3+ regulatory T cells (Tregs) 
that suppress inflammation (Ochoa-Reparaz et al., 2010a; Round and Mazmanian, 2010). 
By promoting Treg development, PSA suppresses immune responses that drive 
inflammation, representing a novel candidate therapy for IBD and MS. Moreover, the 
production of PSA suppresses intestinal immunity directed toward B. fragilis during 
normal homeostatic colonization of animals (Round et al., 2011). Thus PSA is the first 
identified bacterial molecule that promotes mutualism by providing benefits to both 
microbe and mammals during symbiosis. However, the mechanism by which B. fragilis 
delivers PSA to the immune system remains unknown. 
Since the genome of B. fragilis does not encode for known secretion system genes 
(Cerdeno-Tarraga et al., 2005; Kuwahara et al., 2004) and PSA is a large capsular 
polysaccharide (Tzianabos et al., 1992), we reasoned that PSA might be delivered to the 
immune system by OMVs. Indeed, Bacteroides fragilis has been observed to produce 
OMVs during growth (Lutton et al., 1991). Related study also showed that B. fragilis 
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OMVs carry outer membrane associated epitopes, including some polysacchrides by 
immunoblot analysis (Patrick et al., 1996). But whether B. fragilis OMVs specifically 
package PSA, or are able to mediate communication between the bacteria and the host 
immune system, remains unknown. We show herein that PSA is selectively packaged in 
OMVs that are released by B. fragilis. In vivo, OMVs containing PSA prevent 
experimental colitis by suppressing tumor necrosis factor (TNFα) production and T 
helper 17 (Th17) cell development, unlike OMVs that do not contain PSA. OMVs are 
internalized into dendritic cells (DCs), and program DCs to induce the differentiation of 
IL-10-producing Treg cells in a PSA-dependent manner. In vitro, Tregs induced by 
OMVs are functionally suppressive and inhibit T cell proliferation.
20 
2.2 Results 
2.2.1 PSA is Packaged into Outer Membrane Vesicles 
Outer membrane vesicles (OMVs) have been observed in many Gram-negative 
bacteria. For Bacteroides fragilis, OMVs are mostly produced by a subset of bacteria, 
known as the electron dense layer (EDL), which comprises <5% of the population in 
laboratory culture (Patrick et al., 1996). We imaged negatively stained EDL-enriched 
bacteria by transmission electron microscopy. OMVs were abundantly produced by B. 
fragilis (Figure 1A), and could be observed budding from the bacterial envelope (Figure 
1A, higher magnification). Previous studies have shown that deletion of PSA abrogates 
the immunomodulatory capacity of B. fragilis (Mazmanian et al., 2005; Mazmanian et 
al., 2008b). Electron micrographs of a PSA mutant strain (B. fragilisΔPSA) illustrated no 
defect in OMV production, and the size, shape and abundance of OMVs produced were 
indistinguishable from wild-type bacteria (Figure 1A and Figure S1A). To determine if 
PSA is associated with OMVs of B. fragilis, we purified vesicles and probed vesicle 
extracts with anti-sera specific for PSA. OMVs from wild-type bacteria displayed 
immunoreactivity to PSA, unlike OMVs from B. fragilisΔPSA, confirming antibody 
specificity (Figure 1B). In addition to PSA, B. fragilis produces at least 7 other capsular 
polysaccharides that coat the surface of bacterial cells (Krinos et al., 2001; Liu et al., 
2008). While PSB was also detected in vesicle preparations, PSG was absent, possibly 
suggesting regulation of polysaccharide packaging into OMVs (Figure 1B). Immunogold 
labeling of purified vesicles confirmed that PSA is physically associated with OMVs 
(Figure 1C). To verify that the absence of PSA did not alter the molecular composition of 
vesicles, we performed proteomic analysis by mass spectrometry that showed negligible 
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differences in the protein composition between vesicles from wild-type or PSA-mutant 
bacteria (Figure S1B). Together, these findings reveal that B. fragilis packages PSA into 
OMVs, potentially representing a mechanism to deliver immunomodulatory signals to its 
mammalian host. 
2.2.2 OMVs Containing PSA Protect Animals from Experimental Colitis 
Crohn's disease and ulcerative colitis (forms of IBD) are painful and medically 
incurable illnesses of the digestive system (Xavier and Podolsky, 2007). PSA has been 
shown to protect and treat colitis in animal models (Mazmanian et al., 2008b; Round and 
Mazmanian, 2010), including intestinal inflammation induced by 2,4,6- trinitrobenzene 
sulfonic acid (TNBS) (Neurath et al., 2000; Wirtz et al., 2007). To investigate if OMVs 
have therapeutic activity, we orally treated mice with vesicles containing PSA during 
experimental colitis. Control animals rapidly lost weight following rectal administration 
of TNBS (Figure 2A; PBS+TNBS), and did not recover compared to vehicle-treated mice 
that lost minimal weight (Figure 2A; PBS+EtOH). Remarkably, OMVs given orally to 
TNBS animals significantly protected from weight loss (Figure 2A; WT-OMV+TNBS). 
Importantly, when OMVs from B. fragilisΔPSA were administered, weight loss was 
indistinguishable from TNBS-treated animals (Figure 2A; ΔPSA-OMV+TNBS), 
demonstrating that PSA is responsible for preventing wasting disease. Reduction in colon 
length is a hallmark of TNBS colitis (Diaz-Granados et al., 2000). Measurements of 
intact colons (resected from cecum to rectum) showed normal intestinal lengths in 
animals treated with PSA-containing vesicles, but not OMVs lacking PSA (Figure 2B). 
These results show that oral feeding of OMVs corrects weight loss and gross pathology 
of the colon in a preclinical model of IBD. 
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IBD in humans, and colitis in animals, features inflammation driven by innate 
immune cells and CD4+ T cells, resulting in severe intestinal pathology (epithelial 
hyperplasia, sub-mucosal thickening, infiltration of leukocytes) (Xavier and Podolsky, 
2007). Tumor necrosis factor (TNF-α) causes damage to the epithelium and disrupts 
barrier function, and IL-17 promotes neutrophil migration into the gut mediating tissue 
damage. In contrast, IL-10 is protective in numerous animal models of colitis (Lindsay et 
al., 2002), and PSA requires IL-10 expression during protection from disease (Round and 
Mazmanian, 2010). TNFα and IL-17 levels were elevated in colonic tissues, and CD4+ T 
cells from the mesenteric lymph nodes (MLNs) and colons of TNBS-treated animals; 
WT-OMVs suppressed pro-inflammatory cytokines and enhanced IL-10 production 
compared to ΔPSA-OMVs (Figure S2A-C). Upon histological analysis of colonic tissues, 
we observed significant disease in TNBS-treated animals that was ameliorated by oral 
administration of PSA-containing vesicles (Figure 2C). TNBS colitis manifests in focal 
lesions throughout the colon that mimic the pathology observed in Crohn’s disease. 
Finally, clinical symptoms were evaluated by a blinded pathologist to assess disease 
(Wirtz et al., 2007). While all TNBS and ΔPSA-OMV treated animals were severely 
affected, oral administration of WT-OMVs significantly ameliorated disease (Figure 2D). 
We conclude that PSA packaging into OMVs protects animals from the pathological and 
immunological manifestations of experimental colitis, and that OMVs from B. fragilis 
represent a novel candidate therapy for IBD. 
2.2.3 OMV-associated PSA Induces Foxp3 and IL-10 from CD4+ T cells 
The mucosal immune system constitutively surveys the intestinal environment 
and dendritic cells (DCs) sample intestinal contents to coordinate T cell reactions 
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(Rescigno et al., 2001). Purified PSA administered orally to animals is associated with 
CD11c+ DCs in the MLN (Mazmanian et al., 2005). We show that vesicles were taken up 
by bone marrow-derived DCs (BMDCs) regardless of PSA expression (Figure 3A and 
Figure S3A). Confocal microscopy revealed that OMVs (labeled with FITC) appeared as 
punctuate foci throughout the cytoplasm of cells (Figure S3A). DCs rapidly internalized 
vesicles in an actin-dependent manner, as treatment of cells with cytochalasin D 
significantly inhibited vesicle uptake (Figure S3B). Expression of DC activation markers 
(MHCII, CD86) were increased following internalization of OMVs regardless of PSA 
expression (Figure 3B and Figure S3C), indicating that differences in immune effects 
(shown below) are not a result of the inability of DCs to be activated by ΔPSA-OMVs. 
As IL-10 production is known to prevent colitis by suppressing unwanted inflammation 
(Maynard and Weaver, 2008), we examined if OMVs promote anti-inflammatory 
immune responses in cell culture. BMDCs were treated with OMVs, washed, and 
cultured with naïve CD4+ T cells. WT-OMVs induced the expression of IL-10 during in 
vitro DC-T cell co-culture, while minimal IL-10 was detected from DCs alone. Addition 
of anti-CD3 to the co-culture greatly increased IL-10 production, indicating the main 
source of IL-10 was from CD4+ T cells (Figure 3C). Vesicles purified from B. 
fragilisΔPSA induced significantly less IL-10 than WT-OMVs, although an increase was 
observed over media controls. IL-10 production by DCs is known to promote CD4+IL- 
10+ T cell development both in vivo and in vitro (O'Garra et al., 2004)?Accordingly, we 
observed no increase in IL-10 production when wild-type T cells were co-cultured with 
IL-10-/- DCs following treatment with OMVs (Figure 3D), showing that IL-10 
expression by DCs is required to induce IL-10 from CD4+ T cells. 
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CD4+CD25+ T cells that express the transcription factor Forkhead box P3 
(Foxp3) are an important regulatory T cells (Treg) subset shown to protect animals from 
inflammatory and autoimmune diseases (Izcue et al., 2009). Recent studies have shown 
that CD4+CD25+Foxp3+ Tregs can express IL-10, and IL-10 production from Tregs is 
required to prevent intestinal inflammation (Rubtsov et al., 2008). To determine the 
source of IL-10 induced by OMVs, we purified CD4+CD25+ and CD4+CD25- T cells 
following co-culture with DCs and measured the expression of Foxp3 and IL-10 by qRT-
PCR. Remarkably, PSA containing OMVs significantly induced IL-10 expression in the 
CD4+CD25+ Treg population, but not from CD4+CD25- T cells (Figure 3E). Vesicles 
purified from B. fragilisΔPSA were unable to enhance IL-10 production from either T 
cell population compared to media controls. Expression of Foxp3 was increased 
exclusively in CD4+CD25+ T cells by OMVs in a PSA-dependent manner (Figure 3F). 
Furthermore, flow cytometry revealed that WTOMVs stimulated increased IL-10 
production from CD4+CD25+ T cells compared to ΔPSA-OMVs, whereas vesicles with 
or without PSA induced similar baseline levels of IL-10 from CD4+CD25- T cells 
(Figure 3G). 
We sought to determine if PSA could enhance the anti-inflammatory capacity of 
Tregs by measuring their function in cell culture suppression assays. CD4+CD25- 
responder cells were labeled with the intracellular dye CFSE 
(Carboxyfluoresceinsuccinimidyl ester), the fluorescence of which decreases 
proportionally as cells proliferate (Figure 3H; No Tregs). Addition of CD4+CD25+ Tregs 
suppresses cell division (Figure 3H; Media). DCs were pulsed with OMVs, washed and 
cultured with naïve CD4+ T cells; subsequently, CD4+CD25+ Tregs were purified after 
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co-culture and added to CFSE labeled responder CD4+CD25- T cells; proliferation was 
measured by flow cytometry. Tregs recovered from conditions with WT-OMV-treated 
DCs displayed significantly enhanced suppressive capacity compared to CD4+CD25+ T 
cells treated with ΔPSAOMVs (Figure 3H and Figure S3D). Incubation of in vitro 
suppression cultures with a neutralizing anti-IL-10 receptor antibody partially abrogated 
Treg function induced by WT-OMVs, but had no effect on ΔPSA-OMV stimulated Tregs 
(Figure S3E). Collectively, we conclude that OMVs specifically induce functional Tregs 
in cell culture, and that the absence of PSA from OMVs abrogates the ability of B. 
fragilis vesicles to promote Treg activity by dendritic cells. 
Our findings show that delivery of PSA by OMVs underlies the unique probiotic 
properties of B. fragilis, revealing a novel mechanism by which the commensal 
microbiota communicates with the immune system during host-bacterial mutualism.
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2.3 Figures and Legends 
2.3.1 Figure 1. Outer Membrane Vesicles (OMVs) from Bacteroides fragilis Contain PSA  
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(A) Transmission electron microscopy of electron dense layer (EDL) enriched B. fragilis (WT-OMV) and B. fragilisΔPSA (ΔPSA-
OMV) reveals vesicles budding from the bacterial surface. (B) Immunoblot analysis of whole cell (WC) and OMV extracts of bacteria 
show that PSA and PSB are associated with vesicles, while PSG is only found associated with the bacterial cell. Deletion mutants for 
PSA (ΔPSA), PSB (ΔPSB) and PSG (ΔPSG) confirm specificity of each anti-sera. (C) Immunogold labeling of purified OMVs, 
stained with anti-PSA and anti-IgG-colloidal gold conjugate (5 nm), analyzed by electron microscopy shows specific staining for PSA 
only in OMVs from wild-type bacteria but not B. fragilisΔPSA. See also Figure S1. 
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2.3.2 Figure S1, related to Figure 1. Wild-type B. fragilis and B. fragilisΔPSA 
Deletional Mutant Produce Similar Amounts of OMVs and A Similar 
Proteomic Profile  
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(A) Wild-type B. fragilis and the PSA deletion mutant (B. fragilisΔPSA) produce similar 
amounts of OMVs during in vitro culture. Total protein recovered from each OMV 
preparation was normalized by OD600 of the culture at the time of harvest. Error bars 
indicate SEM. Result is shown from >10 combined experiments performed 
independently. p value determined by Student’s t-test. NS: not significant. (B) OMVs 
from wild-type or PSA deletional mutant B. fragilis show no significant difference in 
protein composition. Proteome mass spectrometry shows 100% overlap of the identified 
proteins (>1 unique peptide identified for each protein) between WT-OMVs and ΔPSA-
OMVs. Among all of the identified proteins, we semi-quantitatively compared the 
amount of those relatively abundant proteins according to the number of unique peptides 
identified. The majority of them show no difference between WT-OMV and ΔPSA-
OMV. Results are shown from 3 combined experiments performed independently. 
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2.3.3 Figure 2. OMVs Protect Animals from Experimental Colitis and Intestinal Inflammation in a PSA-dependent 
Manner  
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(A) Weight loss in animals following the induction of TNBS colitis (day 0) measured as reduction from initial weight until day of 
sacrifice (day 4). All groups contained at least 4 animals, with error bars indicating standard error (SEM). Results are representative of 
3 independent trials. * p<0.05; *** p<0.001. (B) Images of colons immediately following resection and quantification of length 
indicated in the bar graph) from vehicle treated (EtOH) and TNBS groups (n=4 animals/group). Error bars indicate SEM. Results are 
shown from 3 combined experiments where each was performed independently. *** p<0.001. NS: not significant. (C) Images from 
hematoxylin and eosin (H & E) stained colon sections representative of each treatment group. (D) Colitis scores from animals 
assigned by a blinded pathologist (G.W.L) according to a standard scoring system (see Experimental Procedures). Each symbol 
represents an individual animal. Results are shown from 3 combined experiments, each performed independently. *** p<0.001. NS: 
not significant. See also Figure S2.
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2.3.4 Figure S2, related to Figure 2. PSA-containing OMVs Suppress Pro-
inflammatory Cytokines and Induce Anti-inflammatory Cytokine Levels in 
Colon Tissue during Experimental Colitis 
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(A) Cytokine transcript analysis by qRT-PCR of RNA recovered from purified CD4+ T 
cells from mesenteric lymph nodes. Each symbol represents a single animal. Error bars 
indicate SEM from 4 animals/ group. Results are shown from 3 combined experiments, 
each performed independently. (B) Cytokine transcript analysis by qRT-PCR from RNA 
recovered from whole colons of each treatment group. Each symbol represents a single 
animal. Error bars indicate SEM. Results are shown from 3 combined experiments 
performed independently. (C) Cytokine analysis by ICCS on CD4+ T cells from colon 
LPL preparations of each treatment group. Each symbol represents a single animal. Error 
bars indicate SEM. Results are representative of 2 independent trials.
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2.3.5 Figure 3. Treatment of DCs with PSA-containing OMVs Induces IL-10 Production and Foxp3 Expression from 
T Cells 
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(A) Flow cytometry (FC) analysis of OMV internalization by DCs. OMVs were labeled with FITC (Fluorescein isothiocyanate) and 
incubated with cultured DCs for various times. Cells were stained with anti-CD11c. Percentages show CD11c+OMV+ cell 
populations. (B) FC plots of DCs incubated with WT-OMVs and ΔPSA-OMVs for various times and stained with anti-CD11c and 
anti- MHCII (Major histocompatibility complex II). Percentages show MHCII+ populations among CD11c+ cells. (C) ELISA analysis 
for IL-10 production from culture supernatants of DCs or DC-T cell co-cultures, where DCs were pulsed with OMVs for 18 hours, 
washed and incubated with or without splenic CD4+ T cells. Supernatants were collected at day 4 of culture. Media samples indicate 
DCs that were not pulsed with OMVs, but otherwise treated identically. Anti-CD3 was added to some samples to demonstrate T cell-
specific responses. Error bars indicate SEM from quadruplicate samples. Results are representative of over 5 independent trials. * 
p<0.05; ** p<0.01. (D) ELISA analysis of DC-T cell co-cultures similar to (C), with IL-10-/- DCs. Error bars indicate SEM from 
quadruplicate samples. Results are representative of 3 independent trials. * p<0.05. ** p<0.01. NS: not significant. (E, F) Transcript 
levels of IL-10 (E) and Foxp3 (F) of RNA recovered from purified CD4+ T cell subsets following in vitro culture with DCs. Co-
cultures were set up as in (C); on day 4, CD4+CD25+ and CD4+CD25- T cells were purified by magnetic bead separation (>95% 
purity) and RNA extracted for qRT-PCR. Relative values were normalized to β-actin. Error bars indicate SEM. Results are shown 
from 3 combined experiments each performed independently. * p<0.05; *** p<0.001. NS: not significant. (G) FC histograms of IL-10 
expression by CD4+ T cell subsets following 4 days of co-culture with DCs treated with OMVs. Splenic CD4+ T cell were purified 
from IL-10-GFP mice, stained with anti-CD4 and anti-CD25 following co-culture, and IL-10 expression measured by GFP expression. 
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Percentages show IL-10+ populations amongCD4+CD25+ and CD4+CD25- subsets. Results are representative of 2 independent 
trials. (H) In vitro suppression of naïve responder cells by purified CD4+CD25+ T cells following co-culture with DCs treated with 
media (control), WT-OMVs and ΔPSA-OMVs. CD4+CD25- responder cells (effector cells; Teff) were pulsed with CFSE, incubated 
with Tregs and stimulated with anti-CD3 and APC (CD4+ T cell depleted splenocytes) for 3 days. Cell proliferation was measured by 
FC as a function of CFSE dilution. Treg:Teff ratios are indicated, and percentages show total proliferating cells. No Treg: 
CD4+CD25- cells only. Numbers above peaks represent number of cell divisions. Results are representative of 3 independent trials. 
See also Figure S3.
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2.3.6 Figure S3, related to Figure 3. OMVs are Internalized via Actin Polymerization and Localized in the 
Cytoplasm of DCs, and Upregulate Co-stimulatory Molecules; Neutralization of IL-10R Signaling Partially 
Abrogates PSA Activity in vitro 
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(A) Fluorescent micrographs of OMV (WT or ΔPSA) internalization by DCs. OMV were labeled with Fluorescein isothiocyanate 
(FITC, green) and incubated with cultured DCs for 2hrs. Cells were fixed and cell membrane was stained with Wheat Germ 
Agglutinin (WGA)-tetramethylrhodamine (red). Scale bar: 7.5µm. (B) Actin polymerization is required for OMV uptake by DCs. 
Flow cytometry analysis of OMV internalization by DCs pre-treated with Cytochalasin D. OMVs were labeled with FITC and 
incubated with cultured DCs for various times (as indicated). Cells were stained with anti-CD11c. Percentages show CD11c+OMV+ 
populations (compare to Figure 3A). (C) WT-OMVs and ΔPSA-OMVs up-regulate the co-stimulatory molecule CD86 (B7.2) for DC 
activation. FC plots of DCs incubated with WT OMVs and ΔPSA-OMVs for various times (as indicated) and stained with anti-CD11c 
and anti-CD86. Percentages show CD86+ populations among CD11c+ cells. (D) Quantification of percentage of CD4+ T cells in each 
proliferating peak (as is labeled in Figure 3H). Error bars indicate SEM. Results are representative of 3 independent trials. * p<0.05; 
** p<0.01; *** p<0.001. (E) Neutralization of IL-10R signaling partially abrogates PSA activity. In vitro suppression assay was set up 
as in Figure 3H except that CFSE labeled responder cells (Teff) were incubated with 20µg/ml of anti-IL-10R (+) or isotype control (-) 
for 1 hour before addition of Tregs purified from DC-T culture under various conditions as indicated. Percentages show total 
proliferating cells. (Treg:Teff=1:4) Results are representative of 2 independent trials.
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Chapter 3 
Growth Arrest and DNA-Damage-Inducible 
Protein (Gadd45α) of Dendritic Cells Mediates 
the Protective Activity of PSA-containing 
OMVs
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3.1 Summary 
Microbial ligands are detected by pattern recognition receptors (Medzhitov, 
2007), and PSA is sensed by toll-like receptor 2 (TLR2) (Wang et al., 2006). Unlike other 
microbial molecules, PSA promotes an anti-inflammatory response upon TLR2 signaling 
(Round et al., 2011). Innate immune cells (such as DCs) have been widely recognized for 
their expression of TLRs and their central role in alerting the innate and adaptive immune 
systems to microbial infection. Our lab recently reported that TLR2 on CD4+ T cells 
responds to purified PSA to promote Treg function (Round et al., 2011). However, a role 
for TLR2 expression by innate immune cells during OMV recognition remains unknown.  
Here, we reveal that TLR2 expression by DCs, and not T cells, is required for recognition 
of PSA within OMVs. Gene expression profiling further led to identification of the 
Growth Arrest and DNA-Damage-Inducible protein (Gadd45α) as being required for 
PSA-mediated TLR2 signaling in DCs. The transfer of OMV-treated DCs to mice 
induced for colitis protects from disease, demonstrating a critical function for DCs in 
promoting PSA activity. Gadd45α deletion in DCs abrogates IL-10 induction by PSA, 
and Gadd45α-/- DCs are unable to provide protection from experimental colitis.
41 
3.2 Results 
3.2.1 Toll-like receptor 2 on DCs is Required to Sense OMV-associated PSA 
To test the requirement for DC-specific TLR2 in PSA recognition, we treated WT 
and TLR2-/- DCs with OMVs and subsequently co-cultured DCs with CD4+ T cells. 
Compared to wild-type DCs, the absence of TLR2 (DCs from TLR2-/- animals) almost 
completely inhibited IL-10 production in response to vesicles (Figure 4A). Both TLR2- 
sufficient and deficient DCs responded equally to super-antigen (SEA) stimulation, 
demonstrating a specific defect in PSA sensing, not a general lack of T cell activation by 
TLR2-/- DCs. In addition, when TLR2-/- T cells were cultured with OMV-pulsed WT 
DCs, production of IL-10 was unaffected (Figure S4A). When OMVs were added 
continuously to DC-T cell co-cultures (thus both cell types were exposed to OMVs), 
TLR2 deletion on DCs led to decreased IL-10 induction (Figure S4B). Furthermore, 
direct treatment of purified CD4+ T cells with PSA-containing OMVs resulted in no IL-
10 up-regulation, unlike stimulation with purified PSA, which activated T cells in a 
TLR2-dependent manner as previously shown (Figure S4C) (Round et al., 2011). 
Therefore, while purified CD4+ T cells can respond directly to PSA, immune responses 
to OMV delivery of PSA require DC, and not T cell, expression of TLR2. Using this 
information, we sought to identify cellular factors involved in PSA-specific, TLR2-
specific signaling by DCs. 
3.2.2 TLR2 Signaling on DCs Induces OMV-specific Gene Expression 
OMVs from Gram-negative bacteria have been shown to contain numerous TLR 
ligands, including lipopolysaccharide (LPS), lipoproteins, peptidoglycan, and bacterial 
DNA (Beveridge, 1999). These molecular patterns are recognized by DCs to drive 
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proinflammatory reactions. PSA represents a novel class of microbial molecule that 
induces immune tolerance. To differentiate between the contributions of PSA and other 
TLR ligands contained within vesicles, we performed global gene expression profiling, 
comparing mRNA levels induced by WT-OMVs and ΔPSA-OMVs in a TLR2- specific 
fashion. Using microarray analysis, 4,712 target probes representing mouse transcripts 
showed expression changes following treatment of DCs with OMVs (Figure 4B). The 
vast majority of these genes were classified as immune-related by the GO Biological 
Process enrichment and the KEGG Pathway enrichment algorithms (Figure 4C). 
Approximately two-thirds of the genes were either up- or down-regulated similarly by 
both WT-OMVs and ΔPSA-OMVs, representing PSA-independent transcript changes 
within DCs (Figure 4D and Figure 4E; blue shaded regions). Of the remaining one-third 
(roughly 1,200), which corresponds to PSA-dependent expression changes, the vast 
majority (98%) of genes were regulated in a TLR2-dependent fashion (Figure 4E). We 
currently do not know of other signaling molecules that sense PSA, and further studies 
are needed to validate the few transcripts that appear to be regulated independently of 
TLR2. However, a list of the top 12 genes that displayed greatest PSA-specific, TLR2-
specific changes again yielded several molecules known to have immune functions 
(Figure 4F). Of these, transcriptional analysis by qRT-PCR verified the microarray 
results for 6 genes, which showed a pattern of being up-regulated by WT-OMVs and 
dependent on TLR2 expression (Figure 4G). Thus, by virtue of delivering PSA to DCs, 
OMVs signal through TLR2 to induce a highly specific gene expression profile. 
3.2.3 DCs Require Gadd45α for Induction of IL-10 
Downstream of TLR2, factors involved in the intracellular signaling pathway(s) 
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that respond to PSA remain completely unknown. Based on its reported role in the 
immune system, we assessed the function of Gadd45α (Growth Arrest and DNA-
Damage- Inducible protein), whose expression by DCs has been shown to promote T cell 
responses (Jirmanova et al., 2007). Gadd45α was induced by OMVs in a PSA specific, 
TLR2- specific manner (see Figure 4G). Co-culture of Gadd45α-/- DCs with WT CD4+ 
T cells resulted in reduced IL-10 production compared to WT DCs treated with WT-
OMVs (Figure 5A). The level of IL-10 expression upon co-culture of Gadd45α-/- DCs 
and CD4+ T cells was identical following treatment with either WTOMVs or ΔPSA-
OMVs. IL-10 production from BMDCs alone treated with OMV was not detectable by 
ELISA (see Figure 3C); thus, using qRT-PCR analysis, we found that IL- 10 expression 
by BMDCs was increased by WT-OMVs, whereas Gadd45α-/- DCs displayed reduced 
IL-10 expression when treated with WT-OMVs or ΔPSA-OMVs (Figure 5B). Gene 
expression profiling had identified several other genes that were coregulated with 
Gadd45α (see Figure 4F and 4G). Of these, BpiI2 and Chac1 are downstream of 
Gadd45α signaling as their expression is lost in Gadd45α-/- DCs following treatment 
with OMVs (Figure S5A). Gadd45α thus appears to be a central signaling component of 
the TLR2 response to OMVs by DCs. 
3.2.4 DCs Mediate Protection from Colitis Through a Requirement for 
Gadd45α 
Colonization of animals with B. fragilis or treatment with PSA ameliorates 
experimental colitis (Mazmanian et al., 2008b; Round and Mazmanian, 2010). However, 
the role of DCs during PSA-mediated protection from disease remains unknown. To 
demonstrate whether DCs require Gadd45α for in vivo PSA activity, we incubated 
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BMDCs with vesicles and transferred cells into mice that were induced for TNBS colitis. 
WT-OMV treated DCs protected animals from disease compared to control (PBS) treated 
cells (Figure 5C). However, treatment of Gadd45α-/- DCs with OMVs prior to transfer 
into wild-type mice resulted in disease scores similar to untreated cells (last column of 
Figure 5C), demonstrating that Gadd45α is required by DCs for PSA-mediated 
protection. Representative histopathology is shown in Figure S5B. Accordingly, 
reduction in colon length is rescued by OMV treatment of WT, but not Gadd45α- 
deficient, DCs (Figure 5D). Finally, we analyzed pro-inflammatory molecules within 
intestinal tissues of TNBS colitis-induced animals following DC transfer. The cytokines 
IFNγ, IL-6 and TNFα were reduced in the colon following transfer of WT DCs incubated 
with OMVs (Figure 5E). Transfer of OMV-treated Gadd45α-/- DCs into animals resulted 
in cytokine and chemokine levels as high as untreated DCs (last column of Figure 5E). 
Collectively, these findings show that OMVs promote tolerogenic DC function during 
protection from colitis and further identify Gadd45α is a factor required for PSA activity, 
revealing a novel signaling pathway by which the human mutualist B. fragilis mediates 
immunologic health.
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3.3 Figures and Legends 
3.3.1 Figure 4. TLR2 on DCs is Required to Sense OMV-associated PSA and 
Induces Genes Specific for OMVs. 
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(A) ELISA analysis of DC-T cell co-cultures similar to Figure 3(C) from WT and TLR2-
/- DCs. SEA: staphylococcal enterotoxin A. Error bars indicate SEM from quadruplicate 
samples. Results are representative of 3 independent trials. * p<0.05. NS: not significant. 
(B) Pie chart showing the number of up-regulated genes (red) and down-regulated genes 
(green) upon stimulation with PSA-containing OMVs during in vitro cultured with 
CD11c+ BMDCs, using a Whole Mouse Genome Microarray analysis. Unaffected genes 
(blue). Only genes with a p value of <0.01 and fold change of >2 were used for 
subsequent analysis. (C) Gene ontology analysis of changes in gene expression levels in 
BMDCs for various biological processes or pathways. (D) Heat-map analysis of gene 
expression in BMDCs from either wild-type or TLR2-/- animals upon OMV stimulation 
reveals that approximately 30% of the genes are either up-regulated or down-regulated in 
a PSA dependent manner and that the majority of the genes are TLR2 dependent. (E) Pie 
charts show that the majority of the genes in BMDCs that respond to PSA are dependent 
on TLR2. (F) List of select genes of highest fold change of expression level upon OMV 
stimulation in a PSA- and TLR2- dependent manner. (G) qRT-PCR analysis of the 
expression level of genes listed in (F) identified and confirmed 6 genes that are 
significantly up-regulated by OMVs in a PSA- and TLR2-dependent manner from 
purified CVD11c+ BMDCs. Results are representative of 3 independent experiments. See 
also Figure S4.
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3.3.2 Figure S4, related to Figure 4. Purified PSA Elicits IL-10 Production 
from T cells in a TLR2-dependent Manner, While PSA-containing OMVs Do 
Not Induce IL-10 Directly from T Cell  
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(A) ELISA analysis for IL-10 production from culture supernatants of DC-T cell co-
cultures, where DCs were pulsed with OMVs for 18 hours, washed and incubated with 
primary CD4+ T cells. Supernatants were collected at day 4 of culture. Media samples 
indicate DCs that were not pulsed with OMVs, but otherwise treated identically. Error 
bars indicate SEM from quadruplicate samples. Results are representative of 2 
independent trials. (B) ELISA analysis for IL-10 production from culture supernatants of 
DC-T cell co-cultures exposed to OMV or media control. Supernatants were collected at 
day 4 of culture. Error bars indicate SEM from quadruplicate samples. Results are 
representative of 2 independent trials. (C) ELISA analysis for IL-10 of culture 
supernatants from T cell cultures exposed to OMVs or purified PSA. Supernatants were 
collected at day 4 of culture. Media samples indicate T cells that were not stimulated, but 
otherwise treated identically. Anti-CD3 was coated on the culture plate to activate T 
cells. Error bars indicate SEM from quadruplicate samples. Results are representative of 
2 independent trials. 
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3.3.3. Figure 5 Gadd45α on DCs is Required for in vitro IL-10 Production and 
Protection from Colitis by OMVs.  
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(A) ELISA analysis of DC-T co-cultures similar to Figure 3(C), but also including 
Gadd45α-/- DCs. Error bars indicate SEM from quadruplicate samples. Results are 
representative of 3 independent trials. *p<0.05. ** p<0.01. NS: not significant. (B) qRT-
PCR analysis of IL-10 transcript levels from either WT or Gadd45α-/- BMDCs after 16-
18hrs incubation with OMVs in vitro. Error bars indicate SEM from triplicate samples. 
Results are representative of 3 independent trials. ** p<0.01. NS: not significant. (C) 
Colitis scores from DC recipient animals induced for TNBS colitis. Each symbol 
represents an individual animal. Results are shown from 2 combined experiments, each 
performed independently. (D) Colon length from mice, at day 2 following TNBS 
treatment. Each symbol represents an individual animal. Error bars indicate SEM from 8 
animals. Results are shown from 2 combined experiments each performed independently. 
* p<0.05. *** p<0.001. NS: not significant. (E) Cytokine analysis by qRT-PCR of RNA 
recovered from whole colon. Each symbol represents an individual animal. Error bars 
indicate SEM from 8 animals. Results are shown from 2 combined experiments, each 
performed independently. See also Figure S5.
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3.3.4 Figure S5, related to Figure 5. Gadd45α is Required in BMDCs to Mediate PSA Activity during Protection 
from Intestinal Inflammation 
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(A) Transcript analysis by qRT-PCR in FACS sorted wild-type and Gadd45a-/- CD11c+ BMDCs of selected genes that were induced 
by PSA-containing OMVs in a TLR2 dependent manner from microarray studies. Error bars indicate SEM. Results are representative 
of 2 independent trials. (B) Images from hematoxylin and eosin (H & E) stained colon sections representative of each treatment group. 
Colitis scores from animals were assigned by a blinded pathologist (G.W.L) according to a standard scoring system (see Experimental 
Procedures). 
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Chapter 4 
Systemic Treatment with PSA Protects Animals 
from Experimental Sepsis via Marginal Zone B 
cells?
 
 
 
 
 
 
 
 
 
?
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4.1 Summary 
As shown in the previous chapters, B. fragilis and its symbiosis molecule PSA 
exerts robust immunomodulatory effects in the gut during both steady state colonization 
and intestinal inflammation (Mazmanian et al., 2008b; Round et al., 2011), We have also 
shown that PSA and PSA-containing OMVs (chapter 2-3) are very effective in protecting 
against intestinal inflammation and are representating potential therapies for IBDs 
(Mazmanian et al., 2008b; Round and Mazmanian, 2010). Nevertheless, we are always 
interested in testing whether B.fragilis or the microbiota have systemic influence on the 
host immune system, and if so, whether PSA can also be used to treat systemic 
inflammatory diseases that are beyond the gut, for instance, sepsis. 
In this chapter, I will discuss our recent findings that uncover the systemic 
immunomodulatory effect of PSA.  We found that systemically administrated PSA could 
protect the animals from LPS-induced endotoxic shock. To our surprise, we found that T 
cells, which had been found critical for the effect of PSA in protecting against 
experimental colitis (chapter 2), were not required for the protective activity of PSA 
against experimental sepsis. Instead, B cells, in particular, Marginal Zone B cells (MZ B 
cells), and the secretion of IgM, seemed to play an important role in mediating this 
protection. Furthermore, transcriptome analysis of MZ B cells isolated from both 
diseased animals and protected animals identified a list of genes that might be important 
players that mediated the protective effect of PSA against endotoxic shock.  
Studies are still under way to reveal the molecular mechanism underlying this 
new protective effect of PSA. The findings will not only potentiate our understanding of 
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the immunomodulatory effect of PSA, but also provide new insight into the interaction 
between commensal bacteria and the immune system of their mammalian host. 
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4.2 Results 
4.2.1 Systemic Treatment of PSA Protects Animals from Experimental Sepsis 
As previsouly shown (Chapter 2-3), oral administration of PSA or PSA containing 
OMVs protects animals from experimental colitis by promoting regulatory responses in 
the host (Mazmanian et al., 2008b). Therefore we first asked whether pre-treatment with 
PSA could lead to protection against experimental sepsis. Here we used LPS-induced 
endotoxic shock model (Chapter 1). LPS induces rapid IL-6 and TNFα responses and 
mice could die from endotoxic shock within a few days (Buras et al., 2005). Interestingly, 
while oral treatment of PSA did not reduce the level of serum IL-6 or TNF-α, systemic 
administration (retro-orbital) of PSA before LPS induction led to a significant decrease of 
these proinflammatory cytokines (Figure 6A and 6B). Along with the reduction of serum 
IL-6 and TNF-α, systemic PSA treatment also resulted in a much higher survival rate 
(Figure 6C). Therefore, PSA, when administered systemically, is able to protect animals 
from experimental sepsis and greatly lower proinflammatory cytokines in the serum. 
More interestingly, we found mice treated with PSA simultaneously with LPS injection 
were still protected from endotoxic shock, as serum TNF-α and IL-6 were largely 
reduced (Figure S6A) and survival rate was much higher (Figure S6B). This result 
suggests the potential of PSA as a therapy for sepsis. PSA given one hour after LPS 
injection, however, appeared to be less effective (Figure S6A and S6B).  
4.2.2 IL-10 or TLR2 is not Required for the Protective Activity of PSA 
against Experimental Sepsis  
Previous studies have shown that both TLR2 and IL-10 are required for the 
protective activity of PSA against experimental colitis (Mazmanian et al., 2008b; Round 
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and Mazmanian, 2010). So we sought to test whether the same protective mechanism of 
PSA was shared against experimental sepsis. To our surprise, neither IL-10 nor TLR2 
were required for the protection against experimental sepsis by PSA. Serum TNF-α level 
was still significantly lowered by PSA treatment in both IL-10-/- mice and TLR2-/- mice 
(Figure 7A and 7C). And upon LPS induction, both strains of mice treated with PSA 
survived endotoxic shock, much better than vehicle treated control mice (Figure 7B and 
7D). This result suggested that the protective mechanisms of PSA against experimental 
colitis and sepsis may be largely divergent.   
4.2.3 Marginal B Cells Mediate the Protection against Experimental Sepsis by 
PSA?
We next asked whether lymphocytes were required for the protective effect of 
PSA against experimental sepsis (Mazmanian et al., 2008b; Round and Mazmanian, 
2010). We found that in Rag-/- mice that had no T or B cells, PSA was no longer 
sufficient to reduce serum TNF-α level (Figure 8A) induced by LPS. Furthermore, the 
mortality of Rag-/- mice after LPS administration was not rescued by PSA (Figure 8B). 
Next, we asked whether T and/or B cells were sufficient for the protective activity of 
PSA against experimental sepsis. To do so, we transferred either T or B cells into Rag-/- 
recipient mice, and tested the effect of PSA to protect these mice from LPS-induced 
endotoxic shock. Interestingly, total T cells (CD3+ splenocytes) or CD4+ T cells (CD4+ 
splenocytes) reconstituted Rag-/- mice were as not responsive to the protective effect of 
PSA, similar to the vehicle treated animals (Figure 8C and 8D). In contrast, PSA could 
protect Rag-/- mice from experimental sepsis when they were reconstituted with CD4+ T 
cell depleted splenocytes (Figure 8C and 8D).  Taken together, these data suggest that a 
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non-T cell population in the spleen could mediate the protective effect of PSA. Notably, 
in our experimental colitis model, PSA acts on CD4+ T cells to promote regulatory 
responses and to suppress the excessive inflammation during disease (Round and 
Mazmanian, 2010). Therefore, the notion that PSA may also influence a cell type other 
than T cells is very intriguing.  
Since B cells are another major cell type in the spleen and represent more than 
half of the splenocytes, we sought to test whether B cells were sufficient to mediate the 
protective activity of PSA. To test this idea, we reconstituted Rag-/- mice with splenic B 
cells and asked whether these mice could be protected from endotoxic shock by PSA. 
Indeed, we found that PSA significantly reduced serum TNF-a levels in these mice upon 
LPS injection (Figure 8E). These mice were also less susceptible to endotoxic shock, 
evident by the increased survival rate compared to that of the vehicle treated ones (Figure 
8F).  
B cells can be categorized into several subsets based on their developmental 
routes and immune functions.  By using this cell transfer method, we further tested which 
specific subset of B cells could mediate the protection against endotoxic shock. Marginal 
zone B cells (MZ B cells) attracted our attention because it was a subset of B cells known 
to participate in the first line of defense against systemic antigens (Pillai et al., 2005). 
Notably, all of the tested Rag-/- mice that were reconstituted with MZ B cells were 
protected against LPS-induced endotoxic shock by PSA (Figure 8G). It is also believed 
that MZ B cells can produce natural antibodies that are specific against bacterial cell wall 
components, such as polysaccharides (Pillai et al., 2005). Moreover, soluble IgM has 
been shown to be protective in experimental sepsis (Reid et al., 1997). Therefore, we 
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utilized knockout mice (sIgM-/-) in which B cells were capable of expressing but not 
secreting IgM (Boes et al., 1998) to test whether IgM secretion was required for MZ B 
cell to mediate the protective effect of PSA. Elimination of IgM secretion from B cells 
completely abolished the protective effect of PSA to reduce serum TNF-α or IL-6 after 
LPS injection (Figure 8H). All these data suggest that a specific B cell population, MZ B 
cells, and the secretion of natural antibody IgM are required for PSA to protect mice 
against experimental sepsis.  
Moreover, reconstitution of Rag-/- recipient mice with MZ B cells harvested from 
mice that were treated with PSA systemically could protect these mice from experimental 
sepsis (Figure 8I and 8J).  The fact that MZ B cells from PSA pre-treated animals could 
transfer protection to untreated recipients indicated that PSA directly or indirectly 
influenced the gene expression profile of MZ B cells and such molecular changes in the 
MZ B cells could be maintained and used to inhibit systemic inflammation. 
4.2.4 Preliminary Data Exploring the Possible Molecular Mechanisms 
underlying the Protective Effect of PSA 
In order to study the molecular mechanism underlying the protective effect of 
PSA mediated by MZ B cells, we examined the whole genome gene expression profiles 
of MZ B cells upon PSA treatment. We first treated animals with either PBS or PSA 
twice before induction of endotoxic shock by LPS. One hour after LPS injection, we 
sacrificed the mice, isolated MZ B cells from the spleens by fluorescent activated cell 
sorting (FACS), and purified mRNA from these cells.  mRNAs of sorted MZ B cells 
from different treatment groups were then sequenced by RNAseq. (1: non-diseased 
group- PBS (i.v.)+PBS (i.p.); 2: diseased group- PBS (i.v.)+LPS (i.p.); 3: protected 
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group- PSA (i.v.)+LPS (i.p.)) RNAseq analysis identified 1,740 genes across the whole 
mouse genome that showed significant difference in expression level between any of the 
two treatments. These genes were then categorized into 8 distinct expression patterns 
among all three treatment groups by K-means clustering analysis (Figure S7). Among the 
8 clusters, cluster 1 represents the genes that were specifically up-regulated by PSA in 
protected animals but not in non-diseased or diseased animals (a full list of genes in this 
cluster is shown in Table S1). Induction of selected genes from this cluster by PSA 
treatment was confirmed by RT-qPCR (Figure 9A) performed on a new set of samples 
prepared independently.  
We also measured IgM level in the serum samples collected from recipient Rag-/- 
mice that were reconstituted with either PBS or PSA treated MZ B cells. Interestingly, we 
observed high levels of IgM from the mice reconstituted with PSA treated MZ B cells but 
not those reconstituted with PBS treated MZ B cells (Figure 9B). This result is consistent 
with the idea that IgM secretion is essential for MZ B cells to mediate the protective 
effect of PSA against sepsis.  
Finally, we used CLP model, which is believed to better mimic human sepsis than 
LPS-induced endotoxic shock, to further examine the protective effect of PSA. We found 
that PSA could also protect mice against CLP (Figure 9C) as mice treated with PSA had a 
higher survival rate than the vehicle controls. Further experiments will be done to test if 
MZ B cells are also involved in this protection. We hope to use CLP model of sepsis to 
verify our findings from the LPS model that PSA protects experimental sepsis via MZ B 
cells and has the potential to become a novel therapy for human sepsis. 	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4.3 Figures and Legends 
4.3.1 Figure 6. PSA can Protect Animal from Endotoxic Shock and Lowers 
Inflammatory Cytokines 
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(A) Serum IL-6 level (4 hours after LPS induced endotoxic shock) measured by ELISA 
from animals that were either orally or intravenously pre-treated with PBS or PSA.  * 
p<0.05; ** p<0.01. (B) Serum TNF-α level (1 hours after LPS induced endotoxic shock) 
measured by ELISA from animals that were either orally or intravenously pre-treated 
with PBS or PSA. *** p<0.001; NS: not significant. (C) Survival curves from animals 
that were intravenously treated with either PBS or PSA, followed by LPS induced 
endotoxic shock. Both groups contained at least 4 animals. 
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4.3.2 Figure S6, related to Figure 6. PSA can Still Lower Inflammation and 
Protect from Death Even When Given after LPS 
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(A) Serum TNF-α and IL-6 levels measured by ELISA from animals that were 
intravenously treated with PBS or PSA either at the same time or 1 hour after LPS 
injection. * p<0.05. (B) Survival curves from animals that were intravenously treated 
with PBS or PSA at the same time or 1 hour after LPS injection. All groups contained at 
least 4 animals. ?
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4.3.3 Figure 7. Neither IL-10 Nor TLR2 is Required for Protection by PSA 
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(A) Serum TNF-α level measured by ELISA from IL-10-/- animals that were 
intravenously treated with either PBS or PSA, followed by LPS induced endotoxic shock. 
* p<0.05. (B) Survival curves from IL-10-/- animals that were intravenously treated with 
either PBS or PSA, followed by LPS induced endotoxic shock. Both groups contained at 
least 4 animals. (C) Serum TNF-α level measured by ELISA from TLR2-/- animals that 
were intravenously treated with either PBS or PSA, followed by LPS induced endotoxic 
shock. *** p<0.001. (D) Survival curves from TLR2-/- animals that were intravenously 
treated with either PBS or PSA, followed by LPS induced endotoxic shock. Both groups 
contained at least 4 animals.  (E) Serum TNF-α level measured by ELISA from TLR2-/- 
animals that were intravenously treated with either PBS or PSA, followed by LPS 
induced endotoxic shock. NS: not significant. (F) Survival curves from Rag-/- animals 
that were intravenously treated with either PBS or PSA, followed by LPS induced 
endotoxic shock. Both groups contained at least 4 animals.  
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4.3.4 Figure 8. MZ B Cells can Mediate Protection by PSA 
?
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(A) Serum TNFα level measured by ELISA from Rag-/- animals that were reconstituted 
with PBS or indicated cells (CD4+ splenocytes, CD3+ splenocytes or CD4 depleted 
splenocytes) and then were intravenously treated with PSA, followed by LPS induced 
endotoxic shock. (B) Survival curves from Rag-/- animals that were reconstituted with 
PBS or indicated cells (CD4+ splenocytes, CD3+ splenocytes or CD4 depleted 
splenocytes) and then were intravenously treated with PSA, followed by LPS induced 
endotoxic shock. All groups contained at least 4 animals. (C) Serum TNF-α level 
measured by ELISA from Rag-/- animals that were reconstituted with B cells and then 
were intravenously treated with either PBS or PSA, followed by LPS induced endotoxic 
shock. (D) Survival curves from Rag-/- animals that were reconstituted with B cells and 
then were intravenously treated with either PBS or PSA, followed by LPS induced 
endotoxic shock. Both groups contained at least 4 animals. (E) Survival curves from Rag-
/- animals that were reconstituted with marginal zone B cells and then were intravenously 
treated with either PBS or PSA, followed by LPS induced endotoxic shock. Both groups 
contained at least 4 animals. (F) Serum TNF-α and IL-6 level measured by ELISA from 
Rag-/- animals that were reconstituted with B cells from either WT or sIgM-/- spleens 
and then were intravenously treated with either PBS or PSA, followed by LPS induced 
endotoxic shock. Error bars indicate SEM from 4 animals. Results are representative of 2 
independent trials.  * p<0.05; ** p<0.01; NS: not significant. (G) Survival curves from 
Rag-/- animals that were reconstituted with marginal zone B cells sorted from wild-type 
donor animals, followed by LPS induced endotoxic shock. Both groups contained 6 
animals. (H) Serum TNF-α and IL-6 level measured by ELISA from Rag-/- animals that 
were reconstituted with marginal zone B cells sorted from wild-type donor animals, 
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followed by LPS induced endotoxic shock. Error bars indicate SEM from 6 animals. ** 
p<0.01.
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4.3.5 Figure S7, related to Figure 8. K-Means Clustering for Differentially 
Expressed Genes in Sorted Marginal Zone B Cells from Animals under 
Different Treatments  
?
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Differentially expressed genes (1,740) were subjected to K-means clustering analysis that 
inferred to 8 differentially expressed patterns. (1: PBS treated animals that were not 
induced disease; 2: PBS treated animals that were induced disease; 3: PSA treated 
animals that were induced disease.) The genes in C1 are listed in Supplemental Table 1.
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4.3.6 Table S1, Related to Figure 8. List of Genes that Were Induced by PSA 
(C1 in Figure S7) 
Gene Name PBS+PBS 
(log2(FPKM)) 
PBS+LPS 
(log2(FPKM)) 
PSA+LPS 
(log2(FPKM)) 
1190002H23Rik 0.913515605 -0.686271644 1.997272536 
1700017B05Rik 3.292141227 2.113724076 4.250523513 
1700064E03Rik 1.714513697 1.274963395 3.675125515 
1810032O08Rik 4.476938955 4.375183038 5.745060561 
3230401D17Rik 4.151558495 3.754375803 5.26761074 
4930415F15Rik -0.054257472 -1.726214468 0.56672896 
9830144P21Rik -0.484081709 -0.677289616 0.911124797 
Abca5 -2.031739638 -0.96096827 0.026413598 
Adamtsl2 -6.64385619 -6.047740283 -4.411279339 
Adm 1.678639854 1.228145852 2.891526898 
Ahr 2.38297706 3.049812428 4.25500639 
AI182371 -6.64385619 -6.640789457 -0.725562937 
Ankrd33b 0.450168697 1.667396082 3.152860206 
Ankrd57 -0.125591739 0.278050944 1.571223383 
Apol8 -6.64385619 -6.640789457 -0.833400687 
Arl5b 0.891045827 1.271168525 2.932184847 
Atf3 4.883845609 3.321283487 5.776500742 
B3gnt7 1.29190998 0.695216557 2.30413308 
B4galt5 -6.64385619 -6.640789457 4.384441359 
Bach1 1.762102144 2.089411476 3.09993487 
Bag3 -0.348575811 -1.114608648 0.879658512 
Bhlha15 -0.16854266 -1.941048702 0.544990085 
Bhlhe40 4.979965872 3.849628052 7.196480596 
Btg3 2.330437931 2.603402268 4.38373441 
C230038L03Rik -2.493678358 -5.12316511 -0.266088297 
Cask -6.64385619 -6.640789457 -0.925130821 
Ccdc86 2.487133865 2.217245094 3.597651183 
Ccdc99 1.188597153 1.307120635 2.710165076 
Ccl3 2.484877983 1.868155534 3.67619451 
Ccr7 5.267442162 3.947865867 6.223001544 
Cdk5r1? 2.515563604 2.707986658 3.843229938 
Coq10b 1.523526829 1.678502652 3.168691496 
Cxcr7 3.611526517 2.90548953 4.471486251 
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Ddit3 4.93929241 3.284743185 5.914001901 
Dnajb4 2.882196968 2.437612018 4.299803759 
Dnajb9 3.695281195 3.44411616 4.960447786 
Dusp14 -2.741165134 -6.640789457 0.330545935 
Dusp4 1.609613144 0.521829122 3.43789526 
Dusp8 -3.646112164 -3.409925501 0.874208499 
Dusp8 -4.568922667 -4.515495812 -1.709121094 
Epha2 -1.833109771 -1.474167744 1.907647392 
Errfi1 0.310025951 0.294184703 1.627582417 
Ets2 3.103113206 2.497348587 4.597994418 
Fam83d -0.791317942 -1.033421681 0.873842701 
Fosl2 -1.132052944 -0.544983891 3.006328836 
Gadd45b 3.33309451 4.662231872 5.646704121 
Gdf15 -6.64385619 -6.640789457 -3.977517057 
Gla 1.963255854 1.603660772 4.770780845 
Glt1d1 -6.078471535 -6.640789457 -4.707694706 
Gm10501 -0.522459437 -0.390646347 2.594455915 
Gm11870 -1.79741302 -3.979487589 0.349415297 
Gm11974 5.541319683 5.867157939 7.008543302 
Gm129 2.992730369 1.626837807 5.706065411 
Gm14928 4.172087423 4.150770848 6.034513647 
Gm15356 -4.497429054 -2.399957321 -1.433655986 
Gm15470 2.737939806 2.986826325 4.536090421 
Gm1564 -5.994315224 -6.640789457 -4.782539755 
Gm15801 3.971497571 3.583310664 5.516887516 
Gm16716 2.361372546 2.963375104 5.930946023 
Gm17024 0.595150343 1.244897961 3.747618715 
Gm17254 -1.691923428 -1.437219956 0.111852835 
Gm17659 -0.106269687 -0.98722156 1.179229417 
Gm614 2.956499061 2.762065359 4.169557368 
Gm6568 2.984545604 2.736593977 4.633638197 
Gm7148 2.345541149 3.2158677 4.786516831 
Gm7278 3.035755858 3.128716358 4.906380253 
Gm7334 2.400466886 2.763075386 4.34295396 
Gm8783 3.971497571 3.583310664 5.516887516 
Gm9115 3.512087794 3.665259752 5.540465445 
Gpr132 3.746957642 3.735222199 4.96649833 
Gpr3 -6.64385619 -6.640789457 -0.212439176 
Grasp 0.855096704 0.160010918 3.389206267 
Haus2 1.692404879 1.839976365 2.984315973 
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Hey1 -3.563843279 -5.335670429 -1.353887685 
Hic1 -1.636579943 -3.441750123 -0.793585338 
Hif3a -1.792187092 -0.950435649 0.280892072 
Hpn -6.64385619 -6.640789457 1.476843609 
Hspa1a 2.337893736 2.503846713 5.697884278 
Hspa1b 2.709504598 3.004485465 6.082292003 
Ifrd1 4.781092134 5.558831939 7.515306397 
Ighv1-20 2.457906803 3.106420194 6.256076627 
Il1r2 -2.17107601 -3.27605274 2.206828017 
Impact 2.1314512 2.2445328 3.787309508 
Ing3 4.290225327 4.516162068 5.633483498 
Insig1 3.014192802 2.794548342 4.532842988 
Irf4 4.571512996 4.787999395 6.086773739 
Irs2 3.151025878 2.454471446 5.761164557 
Kdm6b 3.329166661 3.92697432 5.514751519 
Klf10 0.949004447 1.154161374 3.548366008 
Klf11 1.611956087 1.194164719 3.329546239 
Klf9 0.2131295 0.196974854 2.155853321 
Litaf 3.318601736 3.258754598 4.418849108 
Lrrc66 -6.140035285 -6.640789457 -4.927733151 
Maff 0.890905792 0.279392252 4.220157725 
Map1lc3a 2.977039912 1.377767121 3.806882671 
Map3k6 -5.009025976 -6.640789457 -4.108104994 
Mir155 -6.64385619 -6.640789457 1.534151953 
Mreg 1.931293496 2.432922787 3.765801031 
Mt1 2.784602393 0.506372281 3.424444749 
Mt2 -3.635096822 -0.483484304 0.566986718 
Nfil3 0.682726098 1.149842802 3.061186291 
Ninj1 3.854434575 2.281117953 4.52585782 
Nr4a1 5.821273974 4.653506298 7.245139269 
Nr4a2 2.791511959 2.199403181 4.609263957 
Nr4a3 -0.371885273 1.102559025 3.177143511 
Nrarp -0.633888767 -0.71012337 1.512711797 
Odc1 5.11477512 4.973201224 6.711329443 
Osgin1 2.247733116 1.068561825 3.920537714 
Osgin2 2.458145736 2.354599592 3.989486906 
Pdgfa -6.64385619 -6.640789457 -5.041097059 
Per1 4.276422221 2.898074698 5.961682434 
Phlda1 0.94665601 0.06713726 1.955941076 
Pim3 3.855142563 2.7123994 4.861433995 
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Plau -0.072901515 -1.085776856 2.515240223 
Plk2 2.958783296 2.050847479 4.04770379 
Pmaip1 2.728493064 2.110667748 3.870387401 
Prr7 2.730792097 2.088899856 3.716925534 
Ptger4 3.070233027 2.771147776 4.268356152 
Ptp4a1 3.394555299 3.061375325 4.706282387 
Rem2 -6.64385619 -2.537344917 0.295879072 
Ripk4 -6.64385619 -6.640789457 -1.834551203 
Rnf125 -6.64385619 -2.360043802 0.54248062 
Rrad 2.425647283 1.760212443 3.603615756 
Sertad4 -4.720448355 -6.640789457 -2.102404502 
Siah2 3.773236812 3.368939395 4.761999179 
Slc16a1 0.81614092 0.946153053 2.280132884 
Slc20a1 3.727386831 4.32276489 5.559928396 
Slc38a2 3.654836488 3.924184755 5.047259518 
Smad7 3.311238617 2.717693947 4.32901642 
Snai1 -1.215234722 -0.537822093 1.700036462 
Snora28 6.278999482 6.526145826 8.357527636 
Snora75 4.929284451 5.608164562 7.668068884 
Snord69 7.80469895 9.307017829 10.4348892 
Suv39h2 0.158892797 0.226248955 1.549899683 
Tex15 -6.64385619 -4.433875895 -2.37107081 
Tfrc 3.159059163 3.489160486 4.602935506 
Tgif2 2.745166325 3.651196234 5.168316528 
Tmem88 -0.88576359 -1.004073373 1.005481915 
Tnfrsf12a 1.172596322 -0.572349404 2.211469159 
Trp53inp2 2.711378165 1.135706204 4.097537827 
Utp14b -0.32417865 -0.277022765 1.756762452 
Vegfa -6.64385619 -6.640789457 2.403340627 
Vps18 2.889732465 1.878028037 4.042508598 
Zbtb46 -1.621390721 -0.602326624 0.442434622 
Zc3h12a 4.343208816 4.769499894 5.956545381 
Zfand2a 2.46667932 2.248944415 3.63127555 
Zfp295 1.684001802 1.691157848 3.454859003 
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4.3.7 Figure 9. Preliminary Data Implicating Future Directions 
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(A) qRT-PCR analysis of the expression level of selected genes listed in Supplementary 
Figure 9 identified and confirmed 5 genes that are significantly up-regulated by PSA 
from sorted marginal zone B cells. (B) Serum IgM level measured by ELISA from Rag-/- 
animals that were reconstituted with marginal zone B cells sorted from wild-type donor 
animals that were treated with either PBS or PSA. Error bars indicate SEM from 6 
animals. (C) Survival curves from wild-type animals that were intravenously treated with 
either PBS or PSA, followed by Cecal Ligation and Puncture (CLP). Sham group has 2 
animals and PBS or PSA group has 7 animals. Results are representative of 2 
independent trials.   
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Chapter 5 
Discussion and Perspective 
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5.1 Modulation of Intestinal Immune Responses by PSA-
containing OMVs?
5.1.1 Molecular Communication between the Microbiota and the Immune 
System  
Bacteria shape diverse environments on land, in the oceans, and within plants and 
animals; often, these processes are mediated by secretion of bacterial molecules. 
Regarding interactions with mammals, decades of research has uncovered molecules 
produced by pathogens that promote bacterial invasion into tissues and cells, nutrient 
acquisition and subversion of the immune system. We know of numerous mechanisms by 
which virulence factors are secreted or delivered to mammalian targets. Only recently has 
it become appreciated that symbiotic bacteria also establish molecular communication 
with mammals. The archetypal symbiosis factor of the human microbiota is 
Polysaccharide A (PSA) from Bacteroides fragilis, which ameliorates inflammatory 
disease in animals by inducing immunologic tolerance (Deatherage et al., 2009; Lee and 
Mazmanian, 2010). However, it has remained unknown how PSA is delivered to the 
immune system. The studies described herein illustrate that outer membrane vesicles 
(OMVs) released from the bacterial surface are sufficient to mediate inter-kingdom 
interactions between B. fragilis and the immune system by delivering PSA to DCs. Oral 
treatment of mice with OMVs prevents experimental colitis, whereas vesicles from B. 
fragilisΔPSA are unable to protect animals from wasting disease, histopathology and pro-
inflammatory cytokine production. The requirement of OMVs for this process is 
presently difficult to address, as attempts to delete OMVs from bacteria have thus far 
been unsuccessful, as they may be necessary for viability (Deatherage et al., 2009; Kuehn 
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and Kesty, 2005). However, our work reveals the first paradigm by which a beneficial 
bacterium of the human microbiota selectively delivers a microbial molecule to its host. 
Future studies will aim to understand how other components of B. fragilis OMVs interact 
with the mammalian immune system. 
5.1.2 OMVs Mediate Immunue Tolerance through Activation of Dendritic 
Cells  
In response to sampling both self and foreign antigens, DCs interact with a variety 
of immune cells to coordinate diverse biological responses. The presentation of microbial 
molecules from pathogens to CD4+ T cells is a critical component of a productive 
immune response during infection. Conversely, antigens of the microbiota must be either 
ignored or actively tolerated during long-term colonization to prevent deleterious 
reactions that may adversely affect both microbes and mammals. Indeed, it is believed 
that a critical feature of IBD is uncontrolled immune reactivity to the microbiota. Our 
laboratory has previously shown that PSA induces immunologic tolerance through IL- 
10-producing Foxp3+ regulatory T cells (Tregs), a process that protects animals from 
colitis and promotes colonization by B. fragilis (Round et al., 2011; Round et al., 2010). 
Here we show that OMVs internalized by DCs induce tolerogenic DCs that produce IL-
10, which in turn drive the development of IL-10-producing Tregs. In contrast, OMVs 
from B. fragilisΔPSA do not promote Tregs. Thus, unlike immunity that results from 
recognition of microbial molecules from pathogens, PSA programs DCs to adopt an anti-
inflammatory profile leading to T cell-mediated tolerance and protection from 
experimental colitis. 
Recently, it was shown that intestinal colonization of animals with B. fragilis 
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prevents and treats experimental autoimmune encephalomyelitis (EAE), an animal model 
for human multiple sclerosis (MS) (Ochoa-Reparaz et al., 2010a; Ochoa-Reparaz et al., 
2009). Both EAE and MS involve inflammation in the central nervous system (CNS). 
How does PSA, a symbiosis factor produced in the gut, mediate protection from 
immunity in the brain and spinal cord of animals? Mice protected from disease display an 
increase in the proportions of CD11c+CD103+ DCs, a subset that is known to promote 
Treg differentiation (Ochoa-Reparaz et al., 2010a; Ochoa-Reparaz et al., 2009). 
Interestingly, increased CD103+ DCs and Foxp3+ Treg proportions are only observed in 
the cervical lymph nodes that drain the CNS, but not in other systemic compartments. It 
is currently unknown if the gut is the site of tolerogenic DC induction followed by cell 
migration to the CNS, or if PSA somehow activates DCs outside the intestine. Further, it 
will be interesting to know the subset of DCs that respond to PSA/OMVs. As tolerogenic 
DCs promote Treg development, and Tregs have been shown to suppress inflammation in 
many tissues of the body, it is conceivable that PSA may represent a novel therapy for 
immunologic diseases beyond IBD and MS. 
5.1.3 TLR2 Signaling by DCs is Required for OMV Sensing 
Immune cells recognize microbial ligands through pattern recognition receptors to 
initiate immunologic responses. Previous studies have identified toll-like receptor 2 
(TLR2) as being required for PSA-mediated induction of interferon (IFNγ) (Wang et al., 
2006), as well as IL-10 production from Treg cells (Round and Mazmanian, 2010). 
Furthermore, TLR2-deficient animals are not protected from TNBS colitis by PSA 
treatment (Round and Mazmanian, 2010). Our studies now reveal that TLR2 expression 
by DCs is necessary for the induction of anti-inflammatory responses by OMVs. This 
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phenotype is largely dependent on PSA, although OMVs contain other molecules 
(perhaps lipoproteins) that also increase IL-10 expression through TLR2 (see Figure 4A). 
In contrast, we have previously shown that purified PSA is able to directly induce IL-10 
from CD4+ T cells in the absence of DCs. The DC-dependent pathway described here is 
specific for OMVs, as treatment of T cells alone with OMVs (containing PSA) is unable 
to promote IL-10 production from CD4+ T cells, unlike purified PSA. Furthermore, 
TLR2 deletion on DCs abrogates IL-10 production during in vitro culture with OMVs. 
 The biological context by which DCs and T cells contact PSA during 
colonization by B. fragilis remains unresolved, and further studies involving in vivo 
metabolic labeling of PSA are required to distinguish when, where and how each cell 
type ‘sees’ PSA. However, we speculate that DCs internalize PSA associated with 
OMVs, which traffic through the endocytic pathway to contact T cells at the 
immunologic synapse. This notion is supported by evidence that PSA is presented to 
CD4+ T cells by major histocompatibility complex (MHC II) following internalization 
and processing in the endosome (Cobb et al., 2004). Perhaps deletion of TLR2 on T cells 
abrogates PSA recognition at the immunologic synapse following initial association of 
DCs with OMVs. Thus, both cell types may require TLR2, and addition of purified PSA 
directly to T cells bypasses the requirement for DC expression of TLR2 (Round et al., 
2011). Other models are conceivable as well, and the details of this novel mechanism by 
which the immune system responds to anti-inflammatory microbial ligands are currently 
being addressed. What is clear from our results is that PSA, in the context of OMVs, 
directly activates DCs and not T cells, in a process that requires TLR2. The consequence 
of this interaction leads to the induction of tolerogenic DCs that enhance Treg function 
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and promote protection from inflammatory disease. 
5.1.4 Identification of Gadd45a in the PSA Signaling Pathway 
Following internalization into DCs and engagement of TLR2, OMVs initiate a 
gene expression program that results in IL-10 production by DCs. Although it is known 
that the outcome of PSA sensing by the immune system is Treg induction, nothing is 
known about the intracellular signaling pathway(s) activated by PSA within DCs. We 
analyzed the gene expression profile of DCs treated with OMVs to uncover factors that 
are expressed in a PSA-dependent, TLR2-dependent manner. Of the handful of 
candidates, we focused on Gadd45α (growth arrest and DNA-damage-inducible protein) 
due to its known role in immune responses. In addition to a function in stress responses 
and cell cycle control, Gadd45α has been shown to affect T cell activation by inhibiting 
the alternative p38 pathway in CD4+ T cells (Salvador et al., 2005). More recently, 
Gadd45α expression by DCs was implicated in Th1 polarization in response to 
Toxoplasma gondii antigen stimulation (Jirmanova et al., 2007). Levels of the Th1 
skewing cytokine IL-12 are reduced in Gadd45α-/- DCs, resulting in a non-T cell 
intrinsic reduction in IFNγ+ T cells. We show that Gadd45α is up-regulated upon OMV 
stimulation in a TLR2-specific fashion, and that absence of Gadd45α in OMV-treated 
DCs leads to a defect in IL-10 production. Furthermore, this results in a lack of IL-10 
expression from CD4+ T cells co-cultured with Gadd45α-/- DCs. Transfer of DCs treated 
with OMVs into wild-type animals ameliorates TNBS colitis, demonstrating the 
protective effects of PSA directly on DCs. Transfer of OMV-treated DCs deficient in 
Gadd45α results in no protection from the histopathologic damage and cytokine 
production associated with colitis, revealing that PSA signaling in DCs requires 
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Gadd45α. Intriguingly, Gadd45α deficient animals die at late ages from lupus-like 
autoimmunity (Salvador et al., 2002), a pathology that has been linked to defective Treg 
function (Long and Buckner, 2011). Collectively, these results suggest a model whereby 
PSA from OMVs activates TLR2 to induce expression of Gadd45α, which in turn 
modulates intracellular signaling cascades to promote tolerogenic DC function and 
possibly Treg development during protection from autoimmune and/or inflammatory 
disease. We have not yet directly shown that Gadd45a is required for Treg development 
induced by PSA-containing OMVs, which is currently being addressed in both DC-T 
coculture system and animal models of colitis. It is also worth noting that both PSA and 
Gadd45α could induce or mediate Th1 development (Jirmanova et al., 2007; Mazmanian 
et al., 2005) while here we show that these two molecules are involved in Treg 
development as well. This brings up a new question of how DCs, after sensing PSA, 
could direct T cells to commit to two phenotypically and functionally distinct lineages 
while both of the pathways require Gadd45α.  Since Th1 development was observed in 
the spleen and Treg development was found in the intestine, one possibility is that the 
local environments in the spleen and the intestine differ, which influence the functioning 
of DCs and/ or T cells. As a result, T cells commit to either Th1 or Treg after integrating 
both microbial signals and environmental signals. Another possibility would be the 
difference in other unknown signaling molecules in PSA-Gadd45α pathway. As was 
described in Chapter 3, the microarray analysis has also yielded two other molecules that 
might be downstream of Gadd45α. Further study on the function of those molecules 
would help us to better understand the role of Gadd45α in DCs in mediating different T 
cell responses.
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5.2 Modulation of Systemic Immune Responses by PSA?
5.2.1 B Cells and Sepsis Protection by PSA 
Although it is quite surprising that PSA can act through MZ B cells to achieve 
protection against experimental sepsis, the involvement of B cells in protecting against 
experimental sepsis is not entirely new. A recent study showed that B cell deficient mice 
exhibited decreased inflammatory cytokine and chemokine production and reduced 
survival after sepsis induction. Furthermore, B cells were activated during sepsis, and that 
the activation of B cells was critical for the early inflammatory responses essential to 
control the infection (Kelly-Scumpia et al., 2011). Another study identified a GM-CSF 
producing B cell population in reducing inflammation and limiting bacterial load during 
experimental sepsis. This population of B cell was named innate response activator (IRA) 
B cells because of GM-CSF’s known role in activating innate leukocytes. The authors 
also showed that mice depleted of IRA B cells were extremely susceptible to Cecal 
Ligation and Puncture (CLP) and both inflammatory responses and bacterial burden were 
out of control during disease (Rauch et al., 2012). All these findings support the role of B 
cells in sepsis protection. Nevertheless, the identification of a microbial factor PSA as a 
trigger of protective B cell activation will advance our understanding of the function of B 
cells in sepsis and the development of B cell-mediated new therapies for human sepsis.  
5.2.2 Potential Directions for Future Studies 
As discussed in Chapter 4, we found that systemic treatment with PSA could 
protect animals from LPS-induced endotoxic shock via MZ B cells. Future studies are 
required to figure out how MZ B cells mediate the protective activity of PSA during 
experimental sepsis. 
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Firstly, we have shown that IgM secretion from MZ B cells is required for 
protection by PSA because sIgM-/- MZ B cells failed to support the protective activity of 
PSA when transferred into Rag-/- mice. The immediate hypothesis following this piece of 
data is that PSA can promote IgM secretion from MZ B cells. More specifically, MZ B 
cells may make and secrete LPS-specific IgM upon LPS stimulation; and in PSA treated 
animals, elevated levels of LPS-specific IgM are produced to neutralize LPS. As a result, 
inflammation casued by LPS is reduced. In order to test this hypothesis, we need to either 
detect LPS-specific IgM or measure the residual free LPS level in the serum of protected 
animals. If we observe increased level of LPS-specific IgM or decreased amount of free 
LPS in PSA treated animals, the next question would be how PSA promotes IgM 
secretion from MZ B cells. Further studies on the direct or indirect influences of PSA on 
IgM secretion pathway would be of great interest.  
Notably, with the induction of LPS-specific IgM by PSA being one plausible 
protective mechanism, the possibility that the secreted IgM could be specific to other 
molecules is not entirely ruled out. Since MZ B cells are known to have a BCR repertoire 
specific for bacterial antigens including polysaccharide, it is possible that PSA may also 
induce PSA-specific IgM secretion. And if PSA-specific IgM does exist, whether they are 
involved in the protection or how they contribute to the protection require further 
investigation.?
In addition to the hypotheses that were derived from our experimental evidences, 
we also decided to take an unbiased approach to dissect the mechanism underlying the 
protective activity of PSA via MZ B cells. 
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A transcriptome analysis by deep sequencing was performed on the mRNA of MZ 
B cells isolated from PSA or vehicle treated animals that were induced endotoxic shock. 
We’ve identified and confirmed several genes that are specifically upregulated by PSA 
during protection.?Among those genes, IL-1R2 attracted our attention because it was 
known as a decoy receptor of IL-1 that could block IL-1 signaling (Dinarello, 2009). 
Since IL-1β is also a major proinflammatory cytokine during sepsis, a possible 
hypothesis arose as PSA induced IL-1R2, a negative regulator of IL-1β, to inhibit IL-
1β signaling so that inflammation was controlled once the infection was cleared. In order 
to test this hypothesis, we will measure the levels of IL-1R2 in the serum of PSA treated 
animals to see whether it is induced by PSA or not, and functionally neutralize IL-1R2 in 
vivo to see whether the protective activity of PSA is abolished or not. Besides, there are 
many more genes to be explored from this RNAseq analysis. ?
Additionally, we still do not know whether or not PSA acts directly on MZ B cells 
during protection against sepsis. It is possible that MZ B cells may sense PSA in a TLR2 
independent manner (e.g. by employing an unknown PSA receptor). Alternatively, there 
might be other cell types involved, which may sense PSA and convey its protective effect 
to MZ B cells.  Future studies are necessary to distinguish between these possibilities. 
 Lastly, we have not yet detected PSA or PSA-containing OMVs in the blood of B. 
fragilis-colonized animals. If PSA never reaches the systemic compartments of an animal 
under physiological conditions, what is the biological relevance of our finding that 
systemic treatment of PSA could protect animals from sepsis? One intriguing hypothesis 
would be that PSA has evolved a mechanism to rapidly control the inflammation under 
pathological conditions, e.g., during massive systemic infection. When the gut epithelial 
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barrier is disrupted, gut commensals including B. fragilis may leak out of the intestine. 
When the host mounts systemic proinflammatory responses to clear the massive bacteria 
translocated from the gut, PSA or PSA-containing OMVs derived from B. fragilis (now 
existing systemically) may directly or indirectly influence the activity of MZ B cells and 
produce a rapid anti-inflammatory response to control the inflammation, thus protecting 
the host tissue from being damaged. The advantage of this B cell mediated systemic 
response is its rapidness, as opposed to PSA-induced DC/ T cell-mediated regulatory 
response in the gut, which may take days. As mentioned in Chapter 4, PSA also shows 
protective activity in another murine model of sepsis, the CLP model. We can test the 
above hypothesis by colonizing SPF mice (which normally do not have B. fragilis) with 
B. fragilis and looking for protection following sepsis induction by CLP. This way, B. 
fragilis is released together with other bacteria into the systemic compartments. It 
provides a more “natural” setting to investigate whether PSA can protect animals from 
excessive systemic inflammation under circumstances that PSA is released into the 
circulation. We speculate that these experiments will further support the idea that gut 
commensals have evolved various mechanisms to promote the health of the host, thus to 
achieve their long-term colonization
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5.3 Perspective?
Eons of co-evolution have formed an inextricable connection between mammals 
and our microbiota. With over 100-fold more unique genes in the microbiome than the 
human genome, symbiotic bacteria posses the vast potential to produce molecules, 
destined for their host, which mediate various biological processes. We reveal that B. 
fragilis actively delivers PSA via outer membrane vesicles, uncovering a novel 
mechanism by which the immense molecular coding potential of the microbiome can be 
utilized during mutualism. Sustained, life-long molecular communication between the 
microbiota and mammals bridges the boundaries between kingdoms of life, and supports 
the notion that animals may be viewed as holobionts: a single unit of evolutionary 
selection comprised of a host and its associated microbes (Rosenberg et al., 2009).
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Experimental Procedures 
Bacterial Strains and Culture Conditions. Bacteroides fragilis strain NCTC9343 was 
obtained from the American Type Culture Collection, its isogenic PSA deletion mutant 
(B. fragilisΔPSA) has been described (Coyne et al., 2001). Bacteria were grown either in 
brain heart infusion (BHI) broth (BD Biosciences) supplemented with 0.5µg/ml Hemin 
(Sigma) and 0.5µg/ml Vitamin K (Sigma), or a customized minimum medium which 
contained 8g Glucose, 1% FBS, 0.5µg Hemin, and 0.5µg/ml Vitamin K in 1L of RPMI 
(Invitrogen). 
Mice. C57BL/6 and BALB/c mice were purchased from Taconic Farms (Germantown, 
NY). TLR2 knockout and IL-10 knockout mice were purchased from Jackson 
laboratories. Gadd45α knockout mice were maintained in an NCI pathogen free animal 
facility. IL-10-eGFP mice (Vert-X mice) have been described previously. Foxp3-eGFP 
mice were obtained from Talal A. Chatila (University of California Los Angeles) (Lin et 
al., 2007). All procedures were performed in accordance with the guidelines and the 
approved protocol from the Institutional Animal Care and Use Committee at California 
Institute of Technology.  
Isolation of EDL-enriched Bacteria. Percoll (GE Healthcare) discontinuous density 
gradient centrifugation was used for electron dense layer (EDL) isolation of both 
wildtype B. fragilis and B. fragilisΔPSA, following minor modification from previous 
protocols (Patrick and Reid, 1983). Briefly, using a 20%, 40%, 60%, 80% Percoll 
gradient (diluted with PBS), B. fragilis cells were carefully added on top of the 20% 
Percoll layer. Subsequently, the gradient was centrifuged at 800 x g for 20 minutes at 
room temperature (RT). EDL-enriched bacteria can were recovered from the 40%-60% 
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interface of the gradient after centrifugation. 
OMV Purification and Labeling. B. fragilis OMV isolation was adapted from a 
previously described protocol for the preparation of OMVs from Escherichia coli 
(Horstman and Kuehn, 2000). Briefly, EDL-enriched B. fragilis was grown in customized 
minimal media. OMVs were recovered from the bacteria-free supernatant of the culture 
by centrifugation at 40,000 x g for 2 hours at 4°C, washed twice with PBS and filtered 
through 0.45µm spin columns (Millipore). Total protein concentration of the purified 
OMVs was determined by Bradford assay (BioRad). FITC-labeled OMVs were prepared 
as previously described (Kesty et al., 2004). Briefly, OMVs were incubated in staining 
buffer containing 1mg/ml FITC (Thermo Scientific), 100mM NaCl, 50mM Na2CO3, pH 
9.2) for 1 hour at RT. Labeled OMVs were collected by centrifugation and washed with 
PBS+200mM NaCl before use. 
Electron Microscopy of Bacterial Ultrathin Sections. Ultrathin sections of EDL 
enriched B. fragilis were prepared as previously described (Patrick et al., 1996). Briefly, 
samples were fixed in 2.5% (v/v) glutaraldehyde (Sigma) in cacodylate buffer overnight 
at 4°C, followed by further fixation in osmium tetroxide (1%, w/v) for 3 hours at RT in 
the dark. Ruthenium Red (1mg/ml, Sigma) was included in both of the fixation processes. 
Then fixed samples were embedded in epoxy resin after dehydration in a graded series of 
alcohols. Ultrathin sections (100~200nm) were cut and negatively stained with 2% uranyl 
acetate and lead citrate on formvar/carbon coated copper grids (EMS) before 
visualization by transmission electron microscopy (TEM, FEI Tecnai T12). 
Immunogold Labeling of Purified OMVs. Purified OMVs were applied to 
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formvar/carbon coated gold grids (EMS) and air-dried. Immunogold labeling was 
performed at RT by floating these grids with “OMVs”-side down on a series of small 
drops of antibody and wash solutions. Samples were blocked in 10% FBS for 10 minutes 
after 5 minute incubation in 0.12% glycine. After blocking, samples were further 
incubated with anti-PSA diluted in 10% FBS for 20 minutes, followed by 5 washes with 
PBS. Secondary antibody-IgG conjugated with 5nm gold (kind gift from Dr. Paul 
Webster, House Ear Institute, Los Angeles, CA) was applied to the samples for 20 
minutes, followed again by 5 washes at 4 minutes each with PBS. After labeling, samples 
were fixed in 1% glutaraldehyde for 5minutes and washed extensively by transferring 
grids to drops of PBS and H2O. Contrast staining was performed by placing the grids on 
drops of 3-5% uranyl acetate in 2% methylcellulose for 10minutes on ice. Grids were 
removed from the staining solution and air-dried. Samples covered by a thin film of 
methylcellulose were removed from loop and used for visualization by TEM.  
Chemical (TNBS)-induced Experimental Colitis. BALB/c mice were orally treated 
with PBS, WT-OMV (5µg) or ΔPSA-OMV (5µg) every other day for one week before 
TNBS administration. Mice were anesthetized with isofluorene and rectal administration 
of 2% TNBS (in 50% EtOH, Sigma) was applied through a 3.5F catheter (Instech 
Solomon; SIL-C35) as previously described (Wirtz et al., 2007). For BMDC transfer-
TNBS experiments, WT or ΔPSA-OMV treated WT (C57BL/6) or Gadd45α-/- BMDCs 
were i.p. injected into C57Bl/6 recipient mice 2 hours before TNBS (125mg/kg) 
induction. 
Tissue Pathology Analysis. Mouse colons were fixed in neutral buffered 10% formalin 
(ScyTek Laboratories), embedded in paraffin, sectioned and stained by Pacific Pathology 
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(San Diego, CA). Colitis scores for each colon section were evaluated in a blinded 
fashion by a veterinary pathologist (Dr. Gregory W Lawson) using a standard scoring 
system (Wirtz et al., 2007): 0: No signs of inflammation; 1: Low level of inflammation; 
2: Low level of leukocytic infiltration; 3: High level of leukocytic infiltration, high 
vascular density thickening of colon wall; 4: loss of goblet cells, high vascular density, 
thickening of colon wall. Histology images were taken using light microscopy (Zeiss) at 
20x magnification. 
Quantitative Real-time PCR (qRT-PCR). RNA was collected either from mouse 
tissues using Trizol (Invitrogen) or from purified cells using RNeasy Mini Kit (Qiagen). 
iSCRIPTcDNA synthesis kit (BioRad) was used for conversion of cDNA and IQ SYBR 
Green supermix (BioRad) was used for qRT-PCR. 
Colon Lamina Propria Lymphocytes (LPLs) isolation and Intracellular Cytokine 
Staining (ICCS). Full-length colon was dissected and luminal contents were carefully 
flushed out with ice-cold PBS. Colon epithelium was dissociated and the remaining tissue 
was subjected to enzymatic digestion with collagenase D (0.5mg/ml), dispase (3 units/ml) 
and DNase I (0.5mg/ml). Finally, a 40%-80% Percoll gradient was used to isolate LPLs. 
ICCS of IL-17 and TNFα was performed on LPLs that were re-stimulated in vitro with 
PMA/Ionomycin in the presence of golgi-plug for 4.5 hours, according to manufacturer’s 
protocol (BD Biosciences). 
In vitro BMDC-T Cell Co-culture. Bone marrow was collected from different strains of 
mice and differentiated in vitro in the presence of 20ng/ml GM-CSF (MiltenyiBiotec) for 
bone marrow-derived dendritic cells (BMDCs) as described previously (Mazmanian et 
95 
al., 2005). Cell purity as assessed by CD11c staining was >90%. CD4+ splenic T cells 
were isolated by magnetic microbead purification (Miltenyi Biotec). Cell purity as 
assessed by CD4 staining was>95%. OMV-pulsed BMDCs (10µg/ml OMVs, 1x105 
cells/ml, 12-24 hours) were washed with HBSS to remove unbound OMVs prior to 
incubation with CD4+ T cells (1x106 cells/ml). Co-cultures were performed in round 
bottom 96 well plates with addition of anti-CD3 (0.01µg/ml), TGFβ (2ng/ml), and with or 
without IL-2 (5ng/ml). Supernatants were collected for ELISA (eBiosciences) or cells 
were harvested for qRT-PCR analysis or flow cytometry (FC). 
Flow Cytometry and Staining. BMDCs, for the OMV uptake assay or activation assay, 
were collected and blocked in 5% mouse serum for 30 minutes on ice. After blocking, 
cells were stained with anti-CD11c-APC, anti-MHCII-FITC or anti-CD86-PE 
(eBioscience) for 30 minutes on ice and washed twice with FACS buffer (HBSS without 
Ca2+/Mg2+, 1% FBS, 2mM EDTA, 10mM HEPES) at 4°C before FC analysis. 
Similarly, cells from in vitro BMDC-T cell co-culture were blocked, and stained with 
anti-CD4-APC and anti-CD25-PE similarly except that the cells were re-stimulated using 
PMA/Ionomycin for 4 hours before collecting. All FC was performed with BD 
FACSCalibur and results were analyzed using the FlowJo software (BD Biosciences). 
In vitro Suppression Assay. CD4+CD25+Treg cells purified from BMDC-T cell 
cocultures using magnetic microbeads (Miltenyi Biotec). CD4-depleted mouse 
splenocytes treated with Mitomycin C (Sigma) were used as APCs (1x105 cells/ml). 
CD4+CD25-responder T cells directly purified from mouse spleen were pulsed with 
CFSE for 10minutes at 37°C, followed by first wash with PBS and a second wash with 
culture media, and used immediately (5x105 cells/ml), reffered to as effector T cells 
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(Teff). This assay was conducted in round bottom 96 well plates with an addition of 
5µg/ml of anti-CD3 (eBiosciences) in 200µl. Teff:Treg ratio was titrated and cells were 
collected after 2-3 days of culture for FACS analysis. Anti-IL-10R (20µg/ml, R&D 
Systems) was added as indicated in the results. 
Microarray Hybridization and Data Analysis. RNA was prepared from WT or 
ΔPSAOMV treated CD11c+ BMDCs. RNA samples (1µg total RNA) were labeled with 
fluorescent dyes using the Quick Amp Labeling Kit (Agilent). Microarray (AgilentWhole 
Mouse Genome chip) hybridizations (65°C for 16 hours) and washes were performed 
with Agilent reagents following standard protocols. Microarrays were analyzed using an 
Agilent DNA Microarray Scanner G2565CA, and data were acquired using Agilent's 
Feature Extraction Software version 10.1.1.1. Significant genes were selected based on 
p< 0.01 and fold change >2.0. For enrichment analysis of biological process ontology, 
probe lists were analyzed in DAVID (The Database for Annotation, Visualization and 
Integrated Discovery annotation tools (http://david.abcc.ncifcrf.gov/)) and selected based 
on p< 0.01. 
LPS Induced Endotoxic Shock Model. Balb/c or C57Bl/6 mice were retro-orbitally 
treated with either PSA (100µg/mouse/treatement) or PBS every other day for two times 
before intra-peritoneal injection of LPS (500µg/mice, Sigma). Blood was collected 
(through eye bleed) at both 1 hour and 4 hours after LPS injection to assess serum TNFα 
and IL-6 level. All animals were carefully monitored afterwards to obtain the survival 
curve. In cell transfer experiments, Rag-/- mice were reconstituted with different types of 
cells 12 hours before PSA or PBS treatment; Or Rag-/- mice were reconstituted with cells 
isolated from either PSA or PBS treated donor mice 12 hours before LPS injection. 
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Serum collection. Blood samples were centrifuged at 15,000g for 30 minutes at 4 degree. 
Supernatant (serum) was transferred into new microcentrifuge tubes and stored at -20 
degree or used directly for cytokine ELISA.   
Marginal Zone B Cell Sorting. Splenic B cells were isolated by magnetic microbead 
purification (Miltenyi Biotec). Cells then underwent surface staining of anti-IgM, anti-
CD21 and anti-CD23. Cell sorting was performed on BD FACSAria to isolate marginal 
zone B cells that were IgMhigh CD21high CD23low.  
mRNA Purification and cDNA Library Building.  Mice were retro-orbitally treated 
with either PBS or PSA every other day for two times before intra-peritoneal injection of 
LPS. One hour after LPS injection, mice were sacrificed. Total RNA was extracted from 
3-5 million sorted marginal zone B cells from the spleens of groups of mice undergone 
different treatments using RNeasy Mini Kit (Qiagen), and then subjected to two rounds of 
selection using OligodT coupled magnetic beads (Dynabeads) according to the 
manufacturer’s protocol. About 100 ng polyadenylated mRNA per sample was obtained 
after double selection. cDNA library building was performed as previously described. 
Briefly, RNA was fragmented to an average length of 200 bp by Mg2+-catalyzed 
hydrolysis and then converted into cDNA by random priming. cDNA was then subjected 
to end repairing, adaptor ligation (using Illumina ChIP-seq sample preparation kit #IP-
102-1001), size selection and one round of PCR amplification. 
High-throughput Sequencing. Each cDNA library was sequenced with the Illumina 
Genome Analyzer IIX following the manufacturer’s protocols 
(http://www.illumina.com). 
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RNAseq Data Analysis. Sequence reads from each cDNA library (38 bp, single-read) 
were trimmed to 32 bp long and mapped onto the mouse genome build NCBI37/mm9 
using Bowtie (bowtie-0.12.1, http://bowtie-bio.sourceforge.net/index.shtml) with setting 
‘-v 2 -k 11 -m 10 -t–best–strata’. The mappable data were then processed by the 
ERANGE v. 3.3 RNAseq analysis program (Mortazavi et al., 2008). Assuming total 
transcriptional activity is comparable between different cell types, the obtained data (data 
units in RPKM, reads per kilobase exon model per million mapped reads) were log2 
transformed and linearly normalized among individual samples. At the same time, in 
order to find genes that were changed in expression between any two treatments to a 
statistically significant degree, ERANGE processed data were analyzed by the 
Bioconductor DEGseq program (Wang et al., 2010) 
(http://www.bioconductor.org/packages/2.6/bioc/html/DEGseq.html) (data units in 
FRPM, reads per million mapped reads, method = ‘‘MARS,’’ p < 0.001). This analysis 
yielded 1.740 DEGseq positive genes that had more than a 2-fold change in RNAseq 
reads (after normalization) between any two treatments, and these were defined as 
differentially expressed genes.  
K-Means Clustering. To profile and categorize the behavior of clusters of similarly 
regulated genes by PSA treatment, we first normalized individual mRNA data for the 
1,740 selected genes by the corresponding geometric mean of all three treatments, and 
then performed K-means clustering analysis on the results after log2 transformation 
(Figure S7). K was set at 8 and squared Euclidean distance was used (MATLAB 7.10.0). 
Cecal Ligation and Puncture (CLP) Model. C57Bl/6 mice were retro-orbitally treated 
with either PSA or PBS every other day for two times before the surgery. Surgery was 
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performed according to a standard CLP protocol (Toscano et al., 2011). Briefly, mice 
were treated with eye ointment and buprenorphine before their abdomen were shaved. 
After scrubbing the shaved abdomen, a 1cm-incision was first made in the center of the 
abdomen. Cecum was then located and pulled out of the body cavity for ligation and 
puncture. In order to induce a medium-low level disease, we ligated the cecum at around 
1 cm from the tip of the cecum and used 23G needle to made only one puncture at the tip 
of the cecum. Lastly, the incision was sutured up and mice were under close monitoring 
and regular injection of buprenorthine at each checkpoint. A scoring system was in place 
to assess the wellness of the animals in order to obtain the survival curve. 
Statistical Analyses. Student’s t test and one-way ANOVA were applied for pair-wise 
comparisons and comparisons among >2 groups, respectively. Significant differences 
among groups detected by ANOVA were analyzed using Newman-Keuls test as the post-
hoc test to identify groups exhibiting statistically significant differences. 
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